

## INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

**Acid, fatty**

- differential metabolism of . . . by mycobacteria. Radiometric measurement of. CA-MARGO, E. E., *et al.* . . . . .(O) 200  
exogenous, Effect of growth temperature and, on the lipid composition of *Mycobacterium phlei*. Taneja, R., *et al.* . . . . .(A) 567

**Acid-fast characteristics,**

- acid-fast bacilli in skin smears of leprosy patients. A study of selection sites for.  
Kim, Y. . . . .(A) 391  
non-cultivable acid-fast bacilli in the environment and their relationship to *M. leprae*.  
Occurrence of. Kazda, J. . . . .(A) 262  
oxidative acid-fast staining for non-deparaffinized sections of leprosy tissue. A modified procedure of. Yong, Z., *et al.* . . . . .(A) 131

**Africa,**

- BCG vaccination of children against leprosy in Uganda: final results. Stanley, S. J., *et al.* . . . . .(A) 265  
epidemiological situation in. Cap, J. A. . . . .(A) 258  
Field experience for doctors (Malawi). . . . .(N) 232  
paramedicals, employment sought for. . . . .(N) 119  
Prevalence of dapsone-resistant leprosy to the Burundi. Bourland, J., *et al.* . . . . .(A) 535  
Serum lysozyme (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., *et al.* . . . . .(A) 246

**Albania,**

- leprosy situation in. Lechat, M. F. . . . .(N) 119

**American Leprosy Missions (ALM),**

- Emmanuel Faria named to . . . Board. . . . .(N) 521  
International seminars on leprosy sponsored by . . . and National Hansen's Disease Center. . . . .(N) 381

**Antibody(ies),**

- absence of, to muramyl dipeptide in patients with tuberculosis or leprosy. Bahr, G. M., *et al.* . . . . .(A) 394  
—, responses of leprosy patients to *Mycobacterium leprae* glycolipid-I antigen. Umland, E. T., *et al.* . . . . .(A) 592  
— studies in leprosy and experimental models of the disease, significance of. HARBOE, M. . . . .(E) 342  
— to sulfolipids in human leprosy sera. KHULLER, G. K., *et al.* . . . . .(O) 319  
anticollagen type I and II . . . by an immunoenzymatic technique (ELISA). Detection of: results in rheumatoid arthritis, systemic lupus erythematosus and leprosy.  
Meghlaoui, A. . . . .(A) 250  
antispermatozoal, in leprosy. A study of. GUPTA, S. C., *et al.* . . . . .(O) 43  
class specific anti-*Mycobacterium leprae* . . . assay in lepromatous leprosy (BL-LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et al.* . . .(O) 271  
demonstration of specific antibodies to *Mycobacterium leprae* by counter current electrophoresis. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. . . . .(A) 396  
fluorescent leprosy . . . absorption (FLA-ABS) test for early serodiagnosis of leprosy. Bharadwaj, V. P., *et al.* . . . . .(A) 388  
—, —, —, —, —, Subclinical infection in leprosy; its detection and control by.  
Abe, M., *et al.* . . . . .(A) 257  
IgA and IgM . . . against *Mycobacterium leprae* in cord sera and in patients with leprosy: an indicator of intrauterine infections in leprosy. Melsom, R., *et al.* . . . . .(A) 397  
immunoglobulin class specific . . . in *M. leprae* in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for serodiagnosis of leprosy. Melsom, R., *et al.* . . . . .(A) 397

—, G and M . . . responses to <i>Mycobacterium leprae</i> in relation to various disease patterns. Humoral immunity in leprosy. Touw, J., <i>et al.</i> . . . . .(A)	553
monoclonal, Antigenic diversity of <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium bovis</i> detected by means of. Coates, A. R. M., <i>et al.</i> . . . . .(A)	255
—, production and initial characterization of, to <i>Mycobacterium leprae</i> . Immunochemical characterization of antigens of the leprosy bacillus, including. Miller, R. A., <i>et al.</i> . . . . .(A)	593
—, —, and partial characterization of, to <i>Mycobacterium leprae</i> . Gillis, T. P. and Buchanan, T. M. . . . .(A)	547
—, T lymphocyte subpopulations defined by. Thymus dependent lymphocytes in leprosy. MSHANA, R. N., <i>et al.</i> . . . . .(O)	291
specific . . . to <i>Mycobacterium leprae</i> by counter current electrophoresis, Demonstration of. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. . . . .(A)	396
<b>Antigen(s),</b>	
— of the leprosy bacillus, Immunochemical characterization of, including production and initial characterization of monoclonal antibodies to <i>Mycobacterium leprae</i> . Miller, R. A., <i>et al.</i> . . . . .(A)	593
— of mycobacteria, groups of shared or species specific, A preliminary investigation of the responsiveness or otherwise of patients and staff of a leprosy hospital to. Stanford, J. L., <i>et al.</i> . . . . .(A)	253
—-specific reactions and resistance to <i>Mycobacterium lepraemurium</i> infection in mice, A lack of correlation between. Curtis, J., <i>et al.</i> . . . . .(A)	256
—, —, suppressor cells in subclinical leprosy infection. Stoner, G. L., <i>et al.</i> . . . . .(A)	253
— stimulated human lymphocyte by histamine, Specific modulation of. Nanda, N. K. and Nath, I. . . . .(A)	551
Antigenic analysis of <i>M. leprae</i> in lepromins with reference to the delayed type of hypersensitivity. Sengupta, U., <i>et al.</i> . . . . .(A)	594
Antigenic diversity of <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium bovis</i> detected by means of monoclonal antibodies. Coates, A. R. M., <i>et al.</i> . . . . .(A)	255
armadillo, Correlation between early (Fernandez) and late (Mitsuda) reactions in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of, in three double-blind trials. Bechelli, L. M., <i>et al.</i> . . . . .(A)	547
circulating . . . in onchocerciasis, Detection of. Ouaisi, A., <i>et al.</i> . . . . .(A)	267
Dharmendra, Assessment of. (V) Attempts for purification of specific skin delayed hypersensitivity (DH) inducing . . . from lepromin. Sengupta, U., <i>et al.</i> . . . . .(A)	552
(VI). Skin tests with fractionated nucleic acids. Sinha, S., <i>et al.</i> . . . . .(A)	553
Leprosy ELISA . . . coating buffers and antigens: comparison of <i>M. leprae</i> whole organisms with other mycobacteria. Naka, S. O. and Douglas, J. T. . . . .(A)	600
most immunologically reactive . . . from <i>Mycobacterium tuberculosis</i> H37Ra culture filtrate, Isolation and partial characterization of. Reich, M., <i>et al.</i> . . . . .(A)	567
mycobacterial . . . of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy, Prostaglandin-dependent regulation of the <i>in vitro</i> proliferative response to. Bahr, G. M., <i>et al.</i> . . . . .(A)	129
mycobacterial, in leprosy tissues, Demonstration of. MSHANA, R. N., <i>et al.</i> . . . . .(O)	1
<i>Mycobacterium leprae</i> , effect of dapson treatment on the response to, tuberculin purified protein derivative and non-mycobacterial stimulants. <i>In vitro</i> lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., <i>et al.</i> . . . . .(O)	455
—, —, glycolipid-1, Antibody responses of leprosy patients to. Umland, E. T., <i>et al.</i> . . . . .(A)	592
<i>Mycobacterium lepraemurium</i> . . . at the infection site, Repeated delayed-type hypersensitivity reaction against, do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. . . . .(A)	397
<i>Mycobacterium smegmatis</i> peroxidase, cross-reacting . . . with <i>Mycobacterium leprae</i> . Stavri, D., <i>et al.</i> . . . . .(A)	399
purified . . . of <i>M. leprae</i> and tuberculin PPD, <i>In vitro</i> lymphocyte stimulation using. Closs, O. and Reitan, L. J. . . . .(A)	259
soluble cytoplasmic mycobacterial, Double blind trial on the effect of certain, on the late reactivity to lepromin. HADDAD, N., <i>et al.</i> . . . . .(O)	325

- specific phenolic glycolipid . . . and a related diacyl phtioceral in secretions from  
*Mycobacterium leprae*, Structure and antigenicity of. Hunter, S. W., *et al.* . . . . .(A) 591  
 tuberculous, Radioimmunoassay of. Kadival, G. V., *et al.* . . . . .(A) 567
- Argentina,**  
 Argentine Society of Leprosy annual activities. . . . .(N) 511  
 Leprosy in the Northeast (Zone I). Risso, H. I. . . . .(A) 264  
 Premio Jose M. M. Fernandez. . . . .(N) 119
- Armadillo,**  
 An appetite for. Freiburger, H. F. and Fudenberg, H. H. . . . .(A) 128  
 — antigen in three double-blind trials, Correlation between early (Fernandez) and  
 late (Mitsuda) reactions in children and adolescent non-contacts and without man-  
 ifestations of leprosy, tested with different concentrations of. Bechelli, L. M.,  
*et al.* . . . . .(A) 547  
 — derived *Mycobacterium leprae*, epidemiological evaluation, in Burma, of the skin  
 test reagent LRA6; a cell-free extract from. Part 1. Leprosy patients. SHIELD, M.  
 J., *et al.* . . . . .(O) 436  
 Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD,  
 M. J. and STANFORD, J. L. . . . .(O) 446  
 —, experimentally infected, Borderline leprosy in. JOB, C. K., *et al.* . . . . .(O) 488  
 —, —, —, Lipid constituents of *Mycobacterium leprae* isolated from. Asselineau,  
 C., *et al.* . . . . .(A) 131  
 — lepromin in 50 leprosy patients, comparative study with whole human and. Mitsuda  
 reaction. Zambrano, M. T., *et al.* . . . . .(A) 129  
 — liver, Superoxide dismutase, peroxidatic activity and catalase in *Mycobacterium*  
*leprae* purified with. Wheeler, P. R. and Gregory, D. . . . .(A) 557  
 — livers infected with *Mycobacterium leprae*, Isolation of fastidiously growing my-  
 cobacteria from. PORTAELS, F. and PATTYN, S. R. . . . .(C) 370  
 frozen (−80°C) . . . tissue, Uptake of 3,4-dihydroxy[3H]phenylamine by *Mycobac-*  
*terium leprae* isolated from. Khanolkar, S. R., *et al.* . . . . .(A) 555  
 Multibacillary leprosy in unaltered hosts, with emphasis on . . . and monkeys. Mey-  
 ers, W. M., *et al.* . . . . .(A) 584  
 purified . . . derived *Mycobacterium leprae* in man, Testing of, IMMLEP. . . . .(N) 378  
 Resistance against leprosy in . . . intraspecies differences of Dharmendra. . . . .(A) 250  
 —, —, —, in nine-banded . . . , Intraspecies differences of. Kirchheimer, W. F. and  
 Sanchez, R. M. . . . .(A) 396  
 Tissue response to lepromin, an index of susceptibility of the . . . to *M. leprae* infec-  
 tion; a preliminary report. JOB, C. K., *et al.* . . . . .(O) 177
- Assay(s) (see also ELISA),**  
 beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients; a  
 further probe into cholesterol metabolism, Indirect . . . of. Kannan, K. B., *et al.* . . .(A) 542  
 Class specific anti-*Mycobacterium leprae* antibody . . . in lepromatous leprosy (BL-  
 LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et*  
*al.* . . . . .(O) 271
- Australia,**  
 Change in leprosy control policy. Hargrave, J. C. . . . .(N) 511  
 Leprosy amongst the Aborigines, (Letter to the Editor). McNulty, J. C. . . . .(A) 562
- B663,**  
 ILEP information on side-effects from clofazimine. . . . .(N) 223
- Bacilli,**  
 acid-fast, in skin smears of leprosy patients, A study on selection of sites for.  
 Kim, Y. . . . .(A) 391  
 bacilliferous leprosy patients, Close contacts and non-contacts of. Epidemiological  
 evaluation, in Burma, of the skin test reagent LRA6; a cell-free extract from ar-  
 madillo-derived *Mycobacterium leprae*. Part 2. SHIELD, M. J. and STANFORD,  
 J. L. . . . .(O) 446  
 human and murine leprosy, Ultrastructural features of the multiplication of, in mac-  
 rophages of nude mice. FUKUNISHI, Y., *et al.* . . . . .(O) 68

killed ICRC, Potential antileprosy vaccine from, a clinicopathological study. Deo, M. G., <i>et al.</i> . . . . .(A)	130
leprosy, Cytology of. Hirata, T. . . . .(A)	577
—, Immunochemical characterization of antigens of, including production and initial characterization of monoclonal antibodies to <i>Mycobacterium leprae</i> . Miller, R. A., <i>et al.</i> . . . . .(A)	593
morphology of . . . at different levels of the dermal infiltrate in lepromatous leprosy. GIRDHAR, B. K. and MCDUGALL, A. C. . . . .(O)	477
murine leprosy, Mitogen-induced DNA synthesis in various mouse strains infected with a large or small dose of. Yamaura, N., <i>et al.</i> . . . . .(A)	399
—, —, Phospholipid deacylating activities in. Kashiwabara, Y. and Nakagawa, H. . . . .(A)	588
non-cultivable acid-fast, Occurrence of, in the environment and their relationship to <i>M. leprae</i> . Kazda, J. . . . .(A)	262
normal bacillary lepromin incubated with sera from patients with distinct clinical forms of leprosy, Cutaneous response to. Corona, C. J. J., <i>et al.</i> . . . . .(A)	249
Repeated delayed-type hypersensitivity reaction against <i>Mycobacterium lepraemurium</i> antigens at the infection site do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. . . . .(A)	397
<b>Bacteriology,</b>	
bacteriologically positive leprosy cases, study of 922. KOTICHA, K. K., <i>et al.</i> . . . . .(O)	330
nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time. BARTON, R. P. E., <i>et al.</i> . . . . .(O)	58
present data on the . . . of leprosy. Grosset, J., <i>et al.</i> . . . . .(A)	555
<b>BCG (bacille Calmette-Guérin),</b>	
— and levamisole injection in lepromatous leprosy patients, A study on histopathological change of leproma after. Kim, D. . . . .(A)	396
— vaccine-induced lupus vulgaris. Izumi, A. K. and Matsunaga, J. . . . .(A)	407
Immunotherapy with a mixture of <i>Mycobacterium leprae</i> and . . . in different forms of leprosy and in Mitsuda-negative contacts. CONVIT, J., <i>et al.</i> . . . . .(O)	415
in preschool children, Delayed hypersensitivity after, in relation to their nutritional status. Seth, V., <i>et al.</i> . . . . .(A)	268
<i>Mycobacterium bovis</i> , and <i>Mycobacterium leprae</i> , Ultrastructural characteristics of. BINKHUYSEN, F. and DAS, P. K. . . . .(O)	76
—, . . . vaccination upon <i>Mycobacterium lepraemurium</i> infection, Effect of. Lef-ford, M. J., <i>et al.</i> . . . . .(A)	133
—, —. Lack of a sustained protection against murine leprosy in C3H mice vaccinated with extracts of <i>Mycobacterium lepraemurium</i> in admixture with. TURCOTTE, R. and LEMIEUX, S. . . . .(O)	494
vaccination in leprosy. PRICE, J. E. . . . .(E)	205
vaccination of children against leprosy in Uganda: final results. Stanley, S. J., <i>et al.</i> . . .(A)	265
<b>Belgium,</b>	
The Leper Quarterly collection. Lechat, M. F. . . . .(N)	511
<b>Beta-glucuronidase,</b>	
Immunohistopathologic study of . . . and lysozyme in human leprosy skin lesions. Matsuo, E., <i>et al.</i> . . . . .(A)	599
<b>Biochemistry,</b>	
<i>M. vaccae</i> with <i>M. leprae</i> . Biochemical correlation of. Dutta, A. K., <i>et al.</i> . . . . .(A)	554
peribacillary substance of <i>M. leprae</i> . Biochemical study of. Fukunishi, Y., <i>et al.</i> . . . .(A)	589
<b>Blood,</b>	
— lactic and pyruvic acids in leprosy, Effect of dapsone on. SINHA, S. N., <i>et al.</i> . . . .(O)	468
— staining of the cornea in Hansen's disease; a light- and electron-microscopic study. Yoshimura, M., <i>et al.</i> . . . . .(A)	248
mycobacterial antigens of peripheral . . . lymphocytes from normal donors and from patients with tuberculosis of leprosy, Prostaglandin-dependent regulation of the <i>in vitro</i> proliferative response to. Bahr, G. M., <i>et al.</i> . . . . .(A)	129

- normal . . . donors of three races, Circulating immune complexes in. Pudifin, D. J. and Duursma, J. . . . .(A) 251
- of lepromatous patients with erythema nodosum leprosum, Pharmacologically active mediators of hypersensitivity reactions in. Saha, K. and Lahiri, S. C. . . . .(A) 252
- peripheral . . . and tissues of patients with leprosy, T cell subsets in. Modlin, R. L., *et al.* . . . . .(A) 596
- , —, T and B lymphocytes in leprosy, study of. Hee Chul Eun, *et al.* . . . . .(A) 549
- rabbit red . . . cell rosette formation method, On the immunodepressive effect of rifampicin (RFP) on cell-mediated immunity of guinea pigs examined by. Gidoh, M. and Tsutsumi, S. . . . .(A) 386
- transfusions of fresh . . . donated by healthy but lepromin positive patients, Reversion of the downhill course of active lepromatous leprosy by repeated. Saha, K., *et al.* . . . . .(A) 552
- Borderline leprosy,**
- in an experimentally infected armadillo. Job, C. K., *et al.* . . . . .(O) 488
- tuberculoid, in reaction presenting as photodermatitis: case report. Fekete, E., *et al.* . . .(A) 390
- , *In vitro* lymphocyte stimulation in patients with lepromatous and, effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, tuberculin purified protein derivative and non-mycobacterial stimulants. REITAN, L. J., *et al.* . . .(O) 455
- Bowel,**
- Structure and function of the small . . . in lepromatous leprosy. KUMAR, N., *et al.* . . .(O) 148
- toxicity of clofazimine with special reference to structural and functional status of small intestine, Study of. Kumar, B., *et al.* . . . . .(A) 537
- Brazil,**
- incidence of Hansen's disease in the state of Sao Paulo in 1978. Belda, W. and Lombardi, C. A. . . . . .(A) 257
- severe dermatitis induced by the use of thiacetazone in the treatment of tuberculosis in the state of Rio Grande do Sul. . . . . .(A) 243
- status of leprosy in Rio Grande do Sul. . . . . .(A) 133
- Bulgaria,**
- Leprosy in. Mikhailov, P. and Dimitrova, I. . . . . .(A) 403
- Burma,**
- epidemiological evaluation in, . . . of the skin test reagent LRA6; a cell-free extract from armadillo derived *Mycobacterium leprae*. Part 1. Leprosy patients. SHIELD, M. J., *et al.* . . . . .(O) 436
- Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. . . . . .(O) 446
- epidemiological information on leprosy in the Singu area of Upper Burma. Dominguez, V. M., *et al.* . . . . . .(A) 561
- Tenth meeting of THELEP Steering Committee held in Rangoon. . . . . .(N) 225
- Cancer,**
- and other causes of death among leprosy patients. Tokudome, S., *et al.* . . . . .(A) 248
- Cape Verde,**
- Leprosy in. Loretti, A. and Garbellini, D. . . . . .(A) 263
- Cefoxitin,**
- In vitro* susceptibility of *Mycobacterium fortuitum* and *Mycobacterium chelonae* to. Casal, M. and Rodriguez, F. . . . . .(A) 566
- Cell(s),**
- Antigen-specific suppressor, in subclinical leprosy infection. Stoner, G. L., *et al.* . . . . .(A) 253
- B . . . alloantigen associated with susceptibility to lepromatous leprosy, Identification of. Patarroyo, M. E., *et al.* . . . . . .(A) 264
- culture under regulation of redox potential at environment, Attempts at cultivation of *Mycobacterium leprae* in. Matsuo, Y. and Tatsukawa, H. . . . . .(A) 556
- , —, Use of cycloheximide of cultivating *Mycobacterium leprae* and *Mycobacterium lepraemurium* in. Matsuo, Y. . . . . .(A) 578

— free extract from armadillo-derived <i>Mycobacterium leprae</i> , epidemiological evaluation. in Burma, of the skin test reagent LRA6. Part 1. Leprosy patients. SHIELD, M. J., <i>et al.</i> . . . . .(O)	436
—, —, Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. . . . .(O)	446
—, —, liquid medium by aspartic acid, sucrose, liposome, thymidine, and deoxyuridine (NDLASU medium), Stimulation of growth of <i>Mycobacterium lepraemurium</i> in. Nakamura, M. . . . .(A)	578
—, —, —, by DL-aspartic acid, Stimulation of growth of <i>Mycobacterium lepraemurium</i> in. NAKAMURA, M. . . . .(O)	193
—, —, —, by vitamin K3 and B12, Growth stimulation of <i>Mycobacterium lepraemurium</i> in. Nakamura, M. . . . .(A)	401
—, —, —, Effect of pantoyl lactone on the growth of <i>Mycobacterium lepraemurium</i> in. Nakamura, M. . . . .(A)	556
— mediated and humoral immunity during pregnancy and lactation, Preganacy and leprosy: consequence of alterations of. DUNCAN, M. E., <i>et al.</i> . . . . .(O)	425
—, —, immunity, effect of body temperature and, on the growth of <i>Mycobacterium marinum</i> and <i>Mycobacterium leprae</i> in mice. Lancaster, R. D., <i>et al.</i> . . . . .(A)	556
—, —, —, in lepromatous leprosy using HLA-D-identical siblings, Studies on the defect in. Absence of circulating suppressor . . . and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., <i>et al.</i> . . . . .(A)	553
—, —, —, of guinea pigs examined by rabbit red blood . . . rosette formation method, On the immunodepressive effect of rifampicin (RFP) on. Gidoh, M. and Tsutsumi, S. . . . .(A)	386
— wall components of microorganisms isolated from human leprosy lesions, Chemical identification of. Janczura, E., <i>et al.</i> . . . . .(A)	401
cellular and humoral anti-infective factors, Decreased, in the breast secretions of lactating mothers with lepromatous leprosy. Saha, K., <i>et al.</i> . . . . .(A)	252
immunological implications of necrotic, cellular and vascular changes in leprosy neuritis: light and electron microscopy. Dastur, D. K., <i>et al.</i> . . . . .(A)	400
intra-cellular mycobacteria in experimental mouse tuberculosis, electron microscopy study of. Kanai, K., <i>et al.</i> . . . . .(A)	135
Langerhans', in leprosy, Preliminary observation on. LIU JIHE, <i>et al.</i> . . . . .(O)	316
mononuclear . . . infiltrates in dermal lesions of leprosy, <i>in situ</i> characteristics of. GUPTA, S. K., <i>et al.</i> . . . . .(O)	297
mycobacterial, A fluorescent staining procedure for determining the viability of. KVACH, J. and VERAS, J. R. . . . .(O)	183
plasma . . . dyscrasia, Renal amyloidosis complication of tuberculoid leprosy and, case reports of three patients. Seggie, J. and Gelfand, M. . . . .(A)	546
pre-S-phase . . . cycle kinetics of mitogen-stimulated normal human lymphocytes, Serum inhibitory factor in lepromatous leprosy; its effect on. Potts, R. C., <i>et al.</i> . . .(A)	251
single bacterial, Detection of externally induced impairments in, by laser microbe mass analysis. SEYDEL, U., <i>et al.</i> . . . . .(O)	90
splenic, of such vaccinated mice, Inhibition of foot pad multiplication of <i>M. leprae</i> precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of. Bhide, M. B., <i>et al.</i> . . . . .(A)	400
stabilized sensitized red, Indirect hemagglutination test with. Serology of leprosy. I. Jagannath, C. and Sengupta, D. N. . . . .(A)	395
Suppressor, in experimental murine leprosy. Akiyama, T., <i>et al.</i> . . . . .(A)	595
suppressor mechanisms in leprosy, An investigation of. Shannon, E. J., <i>et al.</i> . . . . .(A)	552
T . . . subpopulations in lepromatous leprosy, Imbalances in. WALLACH, D., <i>et al.</i> . . . . .(O)	282
T . . . subsets in the peripheral blood and tissues of patients with leprosy. Modlin, R. L., <i>et al.</i> . . . . .(A)	596
thymus, effects of carrageenans, splenectomy, and treatment with. The nude rat as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. . . . .(A)	587
tissue culture, relationship between pathogenicity in mice and the ability of <i>M. lepraemurium</i> to grow in. Nomaguchi, H. <i>et al.</i> . . . . .(A)	578

- Ultrastructures of, in lesions of lepromatous and tuberculoid leprosy. Liu Zijun, *et al.* .....(A) 551
- Chemotaxis,**  
of monocytes in hanseniasis. AZULAY, R. D. ....(C) 215  
polymorphonuclear leukocyte (PMN), Thalidomide does not affect. Miyachi, Y. and Ozaki, M. ....(A) 387
- Chemotherapy,**  
combined . . . against *M. leprae*, A model for the development of. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. SEYDEL, J. K. and WEMPE, E. G. ....(O) 20  
in pulmonary tuberculosis, Shortest possible acceptable, effective ambulatory. Mehrotra, M. L., *et al.* ....(A) 408  
of leprosy (Editorial). ....(A) 535  
—, —, (Letter to the Editor). Smith, W. C. S. ....(A) 538  
—, —, for control programmes. ....(A) 536  
—, —, in nude mice. Effect of dapsone (DDS) on nude mice experimentally infected with *Mycobacterium leprae*. Yoneda, K., *et al.* ....(A) 582  
multi-drug . . . of leprosy and type I reaction, Short-term. PFALTZGRAFF, R. E. ....(C) 365  
Third Standardization Workshop for Joint Chemotherapy Trials (Leonard Wood Memorial Laboratory/Cebu/Philippines). Reich, C. V. ....(N) 124
- Child(ren),**  
BCG in preschool, Delayed hypersensitivity, in relation to their nutritional status. Seth, V., *et al.* ....(A) 268  
—, vaccination of, against leprosy in Uganda: final results. Stanley, S. J., *et al.* ....(A) 265  
early (Fernandez) and late (Mitsuda) reactions in, and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigen in three double-blind trials, Correlation between. Bechelli, L. M., *et al.* ....(A) 547  
hypo-pigmented lesions in, A study of. Dutta, R. K. and Murthy, N. ....(A) 389  
Leprosy in. Nouisitou, F. M. ....(B) 125  
of patients with indeterminate leprosy, tuberculoid leprosy, and lepromatous leprosy, Specific skin test responses in. Gimenez, M. and Morini, J. C. ....(A) 395
- China, People's Republic of,**  
Chinese leprologist delegation returned to Bijing after round-the-world investigative tour of eight countries. Ye Gan-yun. ....(N) 512  
Juzam (leprosy) and its treatment in Unani medicine. Zafarullah, M., *et al.* ....(A) 243  
Leprosy in Guangdong Province basically under control. Ma Haide. ....(N) 225  
National Technical Symposium on Leprosy control held in Nanjing. Ye Gan-yun. ....(N) 226  
Second National Leprosy Conference held in Guangzhou. Ye Gan-yun. ....(N) 121
- Cholesterol,**  
— metabolism, Indirect assay of beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients; a further probe into. Kannan, K. B., *et al.* ....(A) 542
- Chromatography,**  
high performance liquid, Determination of three main antileprosy drugs and their main metabolites in serum by. Gidoh, M., *et al.* ....(A) 244  
thin-layer chromatographic analysis of whole-organism methanolysates, Identification of *Mycobacterium chelonae* by. Goodfellow, M. and Minnikin, D. E. ....(A) 267
- Classification, of leprosy,**  
— and treatment of neuropathy in Hansen's disease. Charosky, C. B. ....(A) 267  
Correlation of clinical and histopathological studies in. Dubey, G. K., *et al.* ....(A) 389  
Diversities in clinical and histopathological. Jerath, V. P. and Desai, S. R. ....(A) 542  
pathogenesis and classification of polar tuberculoid leprosy. Ridley, D. S. ....(A) 252
- Clinical,**  
— activity of erythema nodosum leprosum, Immune complexes in leprosy patients from an endemic and nonendemic area and a longitudinal study of the relationship between complement breakdown products and the. Valentijn, R. M., *et al.* ....(A) 399

— and epidemiological features of leprosy in two resettlement villages (Thailand). Vi-thayasai, V., <i>et al.</i> . . . . .(A)	601
— and experimental studies on sulfone resistant leprosy. Li Wenzhong, <i>et al.</i> . . . . .(A)	126
— and histopathological classification of leprosy, Diversities in. Jerath, V. P. and Desai, S. R. . . . .(A)	542
—, —, evaluation, Kveim test in leprosy. Kaur, S., <i>et al.</i> . . . . .(A)	246
—, —, studies in classification of leprosy, Correlation of. Dubey, G. K., <i>et al.</i> . . . . .(A)	389
— diagnosis of dapsone-resistant leprosy. Taylor, P. M. . . . .(A)	546
— evaluation of orofacial lesions of leprosy. Prabhu, S. R. and Daftary, D. K. . . . .(A)	545
— practice, Applicability of Ridley-Jopling scale in. Verma, K. C., <i>et al.</i> . . . . .(A)	393
— clinico-pathological study of so-called immune zones in leprosy. Sahni, U., <i>et al.</i> . . . . .(A)	546
—, —, of testicular involvement in leprosy. Kumar, B., <i>et al.</i> . . . . .(A)	543
distinct . . . forms of leprosy, Cutaneous response to normal bacillary lepromin incubated with sera from patients with. Corona, C. J. J., <i>et al.</i> . . . . .(A)	249
Does rheumatoid arthritis have a clinicopathological spectrum similar to that of leprosy. Panayi, G. S. . . . .(A)	392
indeterminate leprosy; a valid . . . concept. BROWNE, S. G. . . . .(C)	221
<i>Leprosy of the Upper Respiratory Tract. Atlas of Clinical Picture and Notes on the Research (1938–1943).</i> Yosie, Y. . . . .(B)	384
Medical Assistance Programs (MAPS) fellowships provide mission experience. . . . .(N)	234
microcirculation of the nail folds of leprosy, Study of. Hua Wenyuan, <i>et al.</i> . . . . .(A)	549
potential antileprosy vaccine from killed ICRC bacilli; a clinico-pathological study. Deo, M. G., <i>et al.</i> . . . . .(A)	130
short-term . . . trials monitored by mouse foot pad inoculation, A brief review of experiences with. Shepard, C. C. . . . .(A)	245
— spectrum of hanseniasis, Hepatic functions in relation to the. Pacin, A., <i>et al.</i> . . . . .(A)	543
sub-clinical infection in leprosy, Detection of (Editorial). Dharmendra. . . . .(A)	561
—, —, —, in household contacts in India; a preliminary report, Immunoepidemiological studies on. Bharadwaj, V. P., <i>et al.</i> . . . . .(A)	600
—, —, —, its detection and control by fluorescent leprosy antibody absorption (FLA-ABS) test. Abe, M., <i>et al.</i> . . . . .(A)	257
—, —, —, a preliminary report on. Bharadwaj, V. P., <i>et al.</i> . . . . .(A)	561
—, —, with <i>M. leprae</i> , Immunoepidemiological studies on. III. Geographic distribution of FLA-ABS test positive responders with special reference to their possible source of infection. Abe, M., <i>et al.</i> . . . . .(A)	600
—, leprosy infection, Antigen-specific suppressor cells in. Stoner, G. L., <i>et al.</i> . . . . .(A)	253
<b>Clofazimine (B663, Lamprene®),</b>	
activity of, against <i>Mycobacterium intracellulare</i> , Dynamic aspects of. Gangadhar-am, P. R., <i>et al.</i> . . . . .(A)	126
— resistant leprosy; a case report. WARNDORFF-VAN DIEPEN, T. . . . .(O)	139
— therapy, Vitamin A levels of ichthyotic and nonichthyotic skin and plasma of leprosy patients with and without. Bharadwaj, V. P., <i>et al.</i> . . . . .(A)	535
effects of . . . alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy. Van Rensburg, C. E., <i>et al.</i> . . . . .(A)	539
—, on the motility of neutrophils and transformation of lymphocytes from normal individuals, <i>in vitro</i> and <i>in vivo</i> . Gatner, E. M. S., <i>et al.</i> . . . . .(A)	386
in pregnancy complicated by leprosy. Farb, H., <i>et al.</i> . . . . .(A)	243
metabolism of, in leprosy patients. Feng, P. C. C., <i>et al.</i> . . . . .(A)	385
new urinary metabolite of, in leprosy patients. Feng, P. C. C., <i>et al.</i> . . . . .(A)	536
side-effects from, ILEP information on. . . . .(N)	233
Three drugs used most frequently for leprosy are dapsone, rifampin and. . . . .(N)	235
toxicity of, with special reference to structural and functional status of small intestine, Study of. Kumar, B., <i>et al.</i> . . . . .(A)	537
<b>Colombia,</b>	
Fifth Congress of Tropical Disease. . . . .(N)	513
<b>Complement,</b>	
Dapsone and. Schifferli, J. A. and Jones, R. R. . . . .(A)	127
Genetic polymorphisms of properdin factor B(Bf), the second component (C2) and	

- the fourth component (C4) of, in leprosy patients and healthy controls from Thailand. Greiner, J., *et al.* .....(A) 130
- in leprosy, Immune complexes and. Geniteau, M., *et al.* .....(A) 394
- relationship between . . . breakdown products and the clinical activity of erythema nodosum leprosum, Immune complexes in leprosy patients from an endemic and nonendemic area and a longitudinal study of. Valentijn, R. M., *et al.* .....(A) 399
- Control, of leprosy,**
- by fluorescent leprosy antibody absorption (FLA-ABS) test, Subclinical infection in leprosy; its detection and. Abe, M., *et al.* .....(A) 257
- Change in leprosy control policy (Australia). Hargrave, J. C. ....(N) 511
- control in Muheza District (Tanzania), a prevalence survey on leprosy and the possible role of village 10-cell leaders. Von Praag, E. and Mwanemwa, S. A. ....(A) 266
- programmes, Surgical problems of acute onset in leprosy patients and their management in. Prasad, S. B. ....(A) 565
- renewed effort by the government of India. Saxena, M. L. and Johnsen, D. O. ....(N) 375
- control of specificity of skin test reagents. Magnusson, M. ....(A) 263
- control programmes, Chemotherapy of leprosy for. ....(A) 536
- Fourth International Workshop on Leprosy Control in Asia, Kuala Lumpur site of.
- Lechat, M. F. ....(N) 515
- General health education as the main approach to. Hogerzeil, L. M. and Reddy, R. K. ....(A) 561
- Genetic polymorphisms of properdin factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and healthy controls from Thailand. Greiner, J., *et al.* .....(A) 130
- HLA-linked control of the course of *M. leprae* infections. de Vries, R. R. P., *et al.* ..(A) 260
- immunomodulative, by pharmacotherapeutic means, Fundamental studies on. Tsutsumi, S. and Gidoh, M. ....(A) 589
- in Surabaya (Indonesia). Soendijojo, A., *et al.* .....(A) 405
- Leprosy eradication in the developing countries; the required necessary foundation. WEMAMBU, S. N. C. ....(C) 117
- Leprosy in Guangdong Province (China) basically under control. Ma Haide. ....(N) 225
- National Technical Symposium on Leprosy control held in Nanjing (China). Ye Gan-yun. ....(N) 226
- Tuberculosis control: a world review .....(A) 568
- Urban Leprosy Control*. WHO workshop, Bombay (India). ....(B) 383
- Workshop on National Leprosy Control Programme of Varansi Region (India). ....(N) 230
- Corynebacterium,**
- deoxyribonucleic acids of, isolated from human leprosy lesions and of related microorganisms, Base compositions and homologies of. Danhaive, P., *et al.* .....(A) 256
- Costa Rica,**
- Diffuse lepromatous leprosy in. Castro-Coto, A. and Hidalgo-Hidalgo, H. ....(A) 388
- Nodular tuberculoid leprosy in. Hidalgo-Hidalgo, H. and Castro-Coto, A. ....(A) 390
- Crigger-Najjar,**
- Gilbert's syndrome, with Hansen's disease of the dimorphous type. BANERJEE, K. ....(C) 509
- Cuba,**
- Epidemiologic characteristics of leprosy. A study of the prevalence in the City of Santa Clara. Gonzalez, A. N. and Apolinaire Pennin, J. J. ....(A) 260
- Serology to determine syphilis in Hansen's disease patients at Plaza Municipality during 1977. Cardenas, Z. L., *et al.* .....(A) 541
- Cultivation,**
- , the neglected priority. KATO, L. ....(C) 368
- , of *Mycobacterium leprae* and *Mycobacterium lepraemurium* in cell culture. Use of cycloheximide for. Matsuo, Y. ....(A) 578
- , —, —, —, in cell culture under regulation of redox potential at environment, Attempts at. Matsuo, Y. and Tatsukawa, H. ....(A) 556
- , —, —, *lepraemurium in vitro*, and its identification by animal inoculation. Ishaque, M. ....(A) 132

non-cultivable acid-fast bacilli in the environment and their relationship to <i>M. leprae</i> , Occurrence of. Kazda, J. ....(A)	262
<b>Cutaneous,</b>	
allergic . . . vasculitis; Lucio phenomenon. The spectrum of the necrotizing lepra reactions. A proposed intermediate lepra reaction. Peyri, L., <i>et al.</i> ....(A)	545
— leishmaniasis, experimental: disseminated leishmaniasis in genetically susceptible and resistant mice. Scott, P. A. and Farrell, J. P. ....(A)	409
— response to normal bacillary lepromin incubated with sera from patients with distinct clinical forms of leprosy. Corona, C. J. J., <i>et al.</i> ....(A)	249
disseminated . . . rhinosporidiosis treated with dapsone, Case reports. Mahakrisnan, A., <i>et al.</i> ....(A)	135
<b>Cycloheximide,</b>	
for cultivating <i>Mycobacterium leprae</i> and <i>Mycobacterium lepraemurium</i> in cell culture, Use of. Matsuo, Y. ....(A)	578
<b>Damien-Dutton Award,</b>	
Robert Watelet is presented with the 1980. Ross, W. F. ....(N)	377
<b>Dapsone (DDS),</b>	
and complement. Schifferli, J. A. and Jones, R. R. ....(A)	127
blood lactic and pyruvic acids in leprosy, Effect of . . . on. SINHA, S. N., <i>et al.</i> ....(O)	468
clofazimine alone or combined with . . . on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy, Effects of. Van Rensburg, C. E., <i>et al.</i> ....(A)	539
— monotherapy for varying periods of time, The nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with. BARTON, R. P. E., <i>et al.</i> ....(O)	58
— resistant leprosy, clinical diagnosis of. Taylor, P. M. ....(A)	546
—, —, —, Co-incident (simultaneous) . . . sensitive and. McDUGALL, A. C. and Ross, W. F. ....(C)	214
—, —, —, in Korea. Kim, D. ....(A)	386
—, —, —, in Upper Volta, Four cases of. Pattyn, S. R., <i>et al.</i> ....(A)	244
—, —, —, Prevalence of, to the Burundi (Africa). Bourland, J., <i>et al.</i> ....(A)	535
—, —, —, The problem of: diagnosis and management. Laing, A. B. G. ....(A)	244
—, —, <i>Mycobacterium leprae</i> , Increase in prevalence of leprosy caused by. ....(N)	234
—, —, —, Rapid macrophage culture method for detection of. Nath, I., <i>et al.</i> ....(A)	244
— treatment, Class specific anti- <i>Mycobacterium leprae</i> antibody assay in lepromatous leprosy (BL-LL) patients during the first two to four years of. MELSOM, R., <i>et al.</i> ....(O)	271
—, —, on the response to <i>Mycobacterium leprae</i> antigens, The effect of, tuberculin purified protein derivative and non-mycobacterial stimulants. <i>In vitro</i> lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., <i>et al.</i> ....(O)	455
disseminated cutaneous rhinosporidiosis treated with, Case reports. Mahakrisnan, A., <i>et al.</i> ....(A)	135
Fixed genital drug eruption due to. Sinha, M. R. ....(A)	538
in initial treatment of lepromatous leprosy, Once-monthly rifampicin plus daily. Yawalkar, S. J., <i>et al.</i> ....(A)	540
in protein deficiency, Disposition of; an experimental study in mice. Venkatesan, K., <i>et al.</i> ....(A)	540
Intramuscular infection of . . . in therapy for leprosy: A new approach. Modderman, E. S. M., <i>et al.</i> ....(A)	387
isoniazid, prothionamide and . . . against <i>Mycobacterium leprae</i> and some other mycobacteria, Activity of the combination of. Pattyn, S. R., <i>et al.</i> ....(A)	387
nude mice experimentally infected with <i>Mycobacterium leprae</i> , Effect of . . . on. The study of leprosy chemotherapy in nude mice. Yoneda, K., <i>et al.</i> ....(A)	582
paucibacillary leprosy resistant to, Two cases of. Janssens, L. ....(A)	537
phytohaemagglutinin (PHA)-induced lymphocyte transformation, <i>In vitro</i> effect of . . . on. Ghei, S. K., <i>et al.</i> ....(A)	395
pig's thymosin combined with, Pilot-trial of treatment of leprosy by. ....(A)	551

- serum, and serum level of . . . in 87 leprosy patients, Method of determining. Qin-Xue, W., *et al.* . . . . .(A) 127  
 Three drugs used most frequently for leprosy are . . . , rifampin and clofazimine. . . . .(N) 235
- Deformities,**  
 leprosy . . . in a closed community, A survey of. Prasad, S. B. . . . .(A) 406
- Deoxyribonucleic acid (DNA),**  
 base compositions and homologies of . . . of corynebacteria isolated from human leprosy lesions and of related microorganisms. Danhaive, P. *et al.* . . . . .(A) 256  
 isolated from *Mycobacterium leprae*: genome size, base ratio, and homology with other related bacteria as determined by optical DNA-DNA reassociation. Imaeda, T., *et al.* . . . . .(A) 400  
 mitogen-induced . . . synthesis in various mouse strains infected with a large or small dose of murine leprosy bacilli. Yamaura, N., *et al.* . . . . .(A) 399
- Dermatoglyphics,**  
 digital, Features of, in leprosy patients. Baranov, Y. N. and Podoplelov, I. I. . . . .(A) 246  
 in tuberculoid leprosy, Study of. Kapur, T. R. and Verma, R. D. . . . .(A) 543
- Dermatology,**  
 dermal infiltrate in lepromatous leprosy, morphology of bacilli at different levels of. GIRDHAR, B. K. and MCDUGALL, A. C. . . . .(O) 477  
 —, lesions of leprosy, *in situ* characteristics of mononuclear cell infiltrates in. GUPTA, S. K., *et al.* . . . . .(O) 297  
 —, microvasculature in leprosy, Ultrastructure of. TURKEL, S. B., *et al.* . . . . .(O) 164  
 dermatitis, severe, induced by the use of thiacetazone in the treatment of tuberculosis in the state of Rio Grande do Sul (Brazil). . . . .(A) 243  
 Iberian Latin American Congress of Dermatology. . . . .(N) 119  
 Philippine Journal of Dermatology and Leprosy. Reyes-Javier, P. D. . . . .(N) 233
- Dharmendra antigen,**  
 assessment of. V. Attempts for purification of specific skin delayed hypersensitivity (DH) inducing antigen(s) from lepromin. Sengupta, U., *et al.* . . . . .(A) 552  
 VI. Skin tests with fractionated nucleic acids. Sinha, S., *et al.* . . . . .(A) 553
- Diffuse lepromatous leprosy,**  
 in Costa Rica. Castro-Coto, A. and Hidalgo-Hidalgo, H. . . . .(A) 388  
 Lucio phenomenon and . . . pure and primitive in a nonleprosy endemic area. Rea, T. H. . . . .(A) 392
- Dimorphous leprosy,**  
 Gilbert's syndrome (Criggler-Najjar type) with Hansen's disease of the . . . type. BANERJEE, K. . . . .(C) 509  
 transformation of lepromatous leprosy into. Terencio de las Aguas, J. and Rubio, F. C. . . . .(A) 546  
 with outbreaks of hansenic reaction and visceral lesions. . . . .(A) 246
- Diphtheroids,**  
 organisms (LDC) isolated in leprosy patients, Morphologic and biologic properties of. Delville, J., *et al.* . . . . .(A) 554
- Drug(s),**  
 acidic anti-inflammatory, for treatment of leprosy neuritis, Fundamental studies on the possibility of perineurotropic derivatives of. Tsutsumi, S., and Gidoh, M. . . . .(A) 590  
 antileprosy . . . on glycolytic processes in rats infected with *M. leprae*, influence of. Rezaev, A. A. . . . .(A) 245  
 —, three main, and their main metabolites in serum by high performance liquid chromatography, Determination of. Gidoh, M., *et al.* . . . . .(A) 244  
 Bacterial growth kinetics of "M. lufu" in the presence and absence of various . . . alone and in combination. A model for the development of combined chemotherapy against *M. leprae*. SEYDEL, J. K. and WEMPE, E. G. . . . .(O) 20  
 — metabolism in patients with leprosy, *In vivo* and *in vitro*. Kumar, B., *et al.* . . . . .(A) 538  
 multi-drug chemotherapy of leprosy and type 1 reaction, Short-term. PFALTZGRAFF, R. E. . . . .(C) 365

—, regimen pilot project at Oragadam Village (India). . . . .(N)	231
testing . . . activity against <i>Mycobacterium leprae</i> , Statistical analysis of results obtained by two methods for. SHEPARD, C. C. . . . .(O)	96
three . . . used most frequently for leprosy are dapsone, rifampin and clofazimine. . . .(N)	235
<b>Drug sensitivity,</b>	
— test strategy for atypical mycobacteria. Hejny, J. . . . .(A)	407
fixed genital drug eruption due to dapsone. Sinha, M. R. . . . .(A)	538
<b>Electron microscopy,</b>	
— study of intra-cellular mycobacteria in experimental mouse tuberculosis. Kanai, K., <i>et al.</i> . . . . .(A)	135
light and . . . , Immunological implications of necrotic, cellular and vascular changes in leprosy neuritis. Dastur, D. K., <i>et al.</i> . . . . .(A)	249
— — . . . , study, Blood staining of the cornea in Hansen's disease. Yoshimura, M. <i>et al.</i> . . . . .(A)	248
<b>Electrophoresis,</b>	
counter current, Demonstration of specific antibodies to <i>Mycobacterium leprae</i> by. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. . . . .(A)	396
electrophoretic pattern of proteins in lepromatous leprosy. Baji, P. S., <i>et al.</i> . . . . .(A)	540
<b>ELISA test(s) (enzyme-linked immunosorbent assay),</b>	
detection of anti-collagen type I and II antibodies by, results in rheumatoid arthritis, systemic lupus erythematosus and leprosy. Meghlaoui, A. . . . .(A)	250
Leprosy . . . antigen coating buffers and antigens: comparison of <i>M. leprae</i> whole organisms with other mycobacteria. Naka, S. O. and Douglas, J. T. . . . .(A)	600
<b>Enzyme(s),</b>	
diverse hydrolytic lysosomal, of murine peritoneal macrophages, effect of the infection with <i>Mycobacterium lepraemurium</i> on the level of. Phagocytosis in leprosy. 5. ROJAS-ESPINOSA, O., <i>et al.</i> . . . . .(O)	306
serum, profile in tuberculoid leprosy. Bulakh, P. M., <i>et al.</i> . . . . .(A)	541
<b>Epidemiology,</b>	
clinical and epidemiological features of leprosy in two resettlement villages (Thailand). Vithayasai, V., <i>et al.</i> . . . . .(A)	601
epidemiologic characteristics of leprosy. A study of the prevalence in the city of Santa Clara (Cuba). Gonzalez, A. N. and Apolinaire Pennin, J. J. . . . .(A)	260
—, evaluation of leprosy in New York City. Levis, W. R., <i>et al.</i> . . . . .(A)	562
epidemiological aspects and implications of the disappearance of leprosy from Norway; some factors contributing to the decline. Irgens, L. M. . . . .(A)	261
—, information on leprosy in the Singu area of Upper Burma. Dominguez, V. M., <i>et al.</i> . . . . .(A)	561
—, phenomenon, in Burma, of the skin test reagent LRA6; a cell-free extract from armadillo-derived <i>Mycobacterium leprae</i> Part 1. Leprosy patients. SHIELD, M. J., <i>et al.</i> . . . . .(O)	436
Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. . . . .(O)	446
—, —, on decreasing tendency of leprosy disease. Saikawa, K. . . . .(A)	563
—, situation in the Americas (Latin America). Motta, C. P. . . . .(A)	263
—, —, of leprosy in India. Christian, M. . . . .(A)	259
immunological tests as tools in . . . of leprosy, potential of. Kronvall, G. . . . .(A)	263
—, —, in epidemiological work, use of. ten Dam, H. G. and Sansarricq, H. . . . .(A)	266
leprosy epidemiometric model, torments and blessings of. Lechat, M. F. . . . .(A)	263
—, surveys in urban slums; possibilities for epidemiological investigations. Revankar, C. R., <i>et al.</i> . . . . .(A)	404
lymphocyte transformation test in leprosy with special reference to its use in. Bjune, G. . . . .(A)	258
radioimmunoassay and other serological tests and their application to epidemiological work. Harboe, M. . . . .(A)	261
rapid socioeconomic development on the frequency of leprosy in a population, effect of. Saikawa, K. . . . .(A)	264

- Erythema nodosum leprosum (ENL),**  
 clinical activity of, Immune complexes in leprosy patients from an endemic and non-endemic area and a longitudinal study of the relationship between complement breakdown products and the. Valentijn, R. M., *et al.* . . . . .(A) 399  
 lepromatous patients with, Pharmacologically active mediators of hypersensitivity reactions in the blood of. Saha, K. and Lahiri, S. C. . . . .(A) 252  
 precipitated by an imbalance of T lymphocytes, Hypothesis. Mshana, R. N. . . . .(A) 251  
 serum immunoglobulins and autoantibodies during and after. SHARMA, V. K., *et al.* . .(O) 159
- Esterase,**  
 acid non-specific . . . activity in leprosy patients, Investigation of T lymphocytes and. Qiang Nengxian, *et al.* . . . . .(A) 251
- Ethiopia,**  
 All Africa Leprosy and Rehabilitation Training Centre (ALERT) international courses program 1982 . . . . .(N) 226
- Eye(s),**  
 blood staining of the cornea in Hansen's disease; a light- and electron-microscopic study. Yoshimura, M., *et al.* . . . . .(A) 248  
 corneal changes in leprosy. A report of an autochthonous case. Farnarier, G., *et al.* . .(A) 542  
 ocular findings in leprosy; results of a survey in Green Pastures Leprosy Hospital (Nepal). Brandt, F., *et al.* . . . . .(A) 128  
 —, —, —, leprosy patients. A report of a survey in Malunga (Nepal). Brandt, F. and Malla, O. K. . . . .(A) 128
- Fernandez reaction,**  
 correlation between early . . . and late (Mitsuda) reactions in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigens in three double-blind trials. Bechelli, L. M., *et al.* . . .(A) 547
- Filariasis,**  
 bancroftian, in East Godavari district (A.P.) (India). General morbidity, leprosy, scabies and common cold in association with. Rao, C. K., *et al.* . . . . .(A) 545  
 immunology of. . . . .(A) 135
- Finger(s),**  
 of leprosy patients having surgical removal of sublimus tendons. Reddy, N. R. and Kolumban, S. L. . . . .(A) 406  
 smear site selection with particular reference to the . . . . A study in 244 long-treated lepromatous patients. WARNDORFF-VAN DIEPEN, T. . . . .(O) 39  
 wrinkles in leprosy, Formation of. Sheskin, J., *et al.* . . . . .(A) 129
- Fluorescent leprosy antibody absorption (FLA-ABS) test,**  
 diagnosis of leprosy by, Study on. Lee, H. and Kim, Y. . . . .(A) 397  
 — positive responders with special reference to their possible source of infection, Geographic distribution of. Immonoepidemiological studies on subclinical infection with *M. leprae*. III. Abe, M., *et al.* . . . . .(A) 600  
 for early serodiagnosis of leprosy. Bharadwaj, V. P., *et al.* . . . . .(A) 388  
 subclinical infection in leprosy; its detection and control by. Abe, M., *et al.* . . . . .(A) 257
- Foot pad(s),**  
 infection in the hind . . . with *Mycobacterium marinum*, Response in distant lymph nodes of mice to. Mor, N., *et al.* . . . . .(A) 559  
 inhibition of . . . multiplication of *M. leprae* precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice. Bhide, M. B., *et al.* . . . . .(A) 400  
 intraperitoneal vaccination against challenge in the . . . with *Mycobacterium marinum*, Protection of mice by. Ng, H., *et al.* . . . . .(A) 560  
 mouse, Effect of deoxy fructo serotonin (DFS) on the multiplication of *M. leprae* in. Balakrishnan, S., *et al.* . . . . .(A) 535  
 mouse . . . experiments with *M. leprae*, comparison of the skin scrape and skin biopsy methods in. Venkataramanaiah, H. N., *et al.* . . . . .(A) 560

—, —, inoculation, brief review of experiences with short-term clinical trials monitored by. Shepard, C. C. ....(A)	245
response in the hind . . . and popliteal lymph node of C57Bl mice to infection with <i>Mycobacterium marinum</i> . Mor, N., <i>et al.</i> ....(A)	559
<b>France,</b>	
Prix Paul Laviron ....(N)	514
Université Paris VII. Faculté de Médecine Lariboisière—Saint-Louis Certificat de Léprologie. ....(N)	375
<b>Genetic(s),</b>	
— and non- . . . factors in leprosy, potential and limitations for analysis of. Population studies. Kidson, C. ....(A)	262
— polymorphisms of properdin factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and healthy controls from Thailand. Greiner, J., <i>et al.</i> ....(A)	130
genetically susceptible and resistant mice, disseminated leishmaniasis in; Experimental cutaneous leishmaniasis. Scott, P. A. and Farrell, J. P. ....(A)	409
<i>Modern . . . Concepts and Techniques in the Study of Parasites</i> . Michal, F. ....(B)	525
<b>Genome,</b>	
— size, base ratio, and homology with other related bacteria as determined by optical DNA-DNA reassociation: DNA isolated from <i>Mycobacterium leprae</i> . Imaeda, T., <i>et al.</i> ....(A)	400
<b>Germany, Federal Republic of,</b>	
Deutsche Aussätzigen-Hilfswerke (DAHW) activities in leprosy. Kirchheimer, W. F. ..(N)	226
German Leprosy Relief Association's 25th anniversary. ....(N)	227
Hermann Kober receives Distinguished Service Cross from German government. ....(N)	513
<b>Gilbert's syndrome,</b>	
(Crigler-Najjar type) with Hansen's disease of the dimorphous type. BANERJEE, K. ..(C)	509
<b>Glomerulonephritis,</b>	
immunological bases of, in leprosy; a brief review. DATE, A. ....(E)	351
in leprosy. Ng, W. L., <i>et al.</i> ....(A)	391
<b>Glycolysis,</b>	
influence of antileprosy drugs on glycolytic processes in rats infected with <i>M. leprae</i> . Rasaev, A. A. ....(A)	245
<b>Guatemala,</b>	
Patrons for Action Against Leprosy of Guatemala elect new officers. Samayoa, J. M. ..(N)	381
<b>Guinto, R. S.,</b>	
Notice of death ....(N)	516
<b>H37Ra,</b>	
<i>Mycobacterium tuberculosis</i> . . . culture filtrate, Isolation and partial characterization of the most immunologically reactive antigen from. Reich, M., <i>et al.</i> ....(A)	567
<b>Hand(s),</b>	
muscular wasting in the . . . from leprosy, Augmentation in. Harahap, M. ....(A)	267
<b>Hansen's disease,</b>	
chemotaxis of monocytes in hanseniasis. AZULAY, R. D. ....(C)	215
College of Hansenology of the Endemic Countries founded. Azulay, R. D. and Mot- ta, C. P. ....(N)	225
cornea in, Blood staining of the; a light- and electron-microscopic study. Yoshimura, M., <i>et al.</i> ....(A)	248
diagnosing, A test of wrinkle formation caused by soaking in warm water in. Shes- kin, J., <i>et al.</i> ....(A)	247
dimorphous hanseniasis with outbreaks of hansenic reaction and visceral lesions. ....(A)	246
Gilbert's syndrome (Crigler-Najjar type) with, of the dimorphous type. BANERJEE, K. ..(C)	509
hepatic functions in relation to the clinical spectrum of hanseniasis. Pacin, A., <i>et al.</i> ..(A)	543
incidence of, in the state of Sao Paulo in 1978 (Brazil). Belda, W. and Lombardi, C. A. ....(A)	257

lactic dehydrogenase isoenzymes in the sera of hanseniasis patients. Garcia, R., <i>et al.</i> . . .(A)	542
name changes reflect trends. ROTBERG, A. . . . .(C)	117
National Hansen's Disease Center, Audio-visual loan program at. . . . .(N)	516
—, —, —, —, International seminars on leprosy sponsored by American Leprosy Missions and. . . . .(N)	381
neuropathy in, Classification and treatment of. Charosky, C. B. . . . .(A)	267
1981–1982 Associação Brasileira de Hansenologia Board of Directors. Bechelli, L. M. . .(N)	122
Penikese Hospital; A Massachusetts hospital for the treatment of. Sabin, T. D. . . . .(A)	126
syphilis in . . . patients at Plaza Municipality (Cuba) during 1977. Serology to determine. Cardenas, Z. L., <i>et al.</i> . . . . .(A)	541
—, in patients with. MURRAY, K. A. . . . .(O)	152
<b>Hawaii,</b>	
immigration and leprosy in. WORTH, R. M. and BOMGAARS, M. R. . . . .(O)	335
<b>Heiser Program, The</b>	
first five years. . . . .(N)	379
for research in leprosy; 1983 opportunities. . . . .(N)	380
<b>Hepatitis,</b>	
— A and B virus markers (anti-HAV, HBsAf, HBsAb, HBeAg, HBeAb) in leprosy patients. Ferlazzo, B., <i>et al.</i> . . . . .(A)	390
— B virus infection in patients with leprosy; A serological study in leprosarium in Northern Nigeria. Fankule, Y. M. and Whittle, H. C. . . . .(A)	390
<b>Histamine,</b>	
specific modulation of antigen stimulated human lymphocyte by. Nanda, N. K. and Nath, I. . . . .(A)	551
<b>Histoid leprosy,</b>	
observations on ultrastructure of. LIU JIHE, <i>et al.</i> . . . . .(O)	471
unusual presentation of. Singh, M., <i>et al.</i> . . . . .(A)	393
<b>Histology,</b>	
histologic profile in apparently normal skin of leprosy patients. Sakuntala, R., <i>et al.</i> . .(A)	552
of indeterminate leprosy. LIU TZE-CHUN, <i>et al.</i> . . . . .(O)	172
<b>Histopathology,</b>	
clinical and histopathological studies in classification of leprosy, Correlation of. Dubey, G. K., <i>et al.</i> . . . . .(A)	389
histopathological change of leproma after BCG and levamisole injection in lepromatous leprosy patients, study on. Kim, D. . . . .(A)	396
—, features of leprosy lesions in the skin and peripheral nerve, Discrepancy in. Report of a preliminary study. Srinivasan, J., <i>et al.</i> . . . . .(A)	553
Kveim test in leprosy; a clinical and histopathological evaluation. Kaur, S., <i>et al.</i> . . . .(A)	246
Liver in leprosy. II. Histopathological changes. Robins, K., <i>et al.</i> . . . . .(A)	398
nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time. BARTON, R. P. E., <i>et al.</i> . . . . .(O)	58
of primary indeterminate leprosy. Liu Zijun, <i>et al.</i> . . . . .(A)	550
<b>HLA,</b>	
— and sporadic tuberculoid leprosy; a population study in Maharashtra (India). van Eden, W., <i>et al.</i> . . . . .(A)	405
— D-identical siblings, Studies on the defect in cell-mediated immunity in lepromatous leprosy using. Absence of circulating suppressor cells and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., <i>et al.</i> . . . . .(A)	553
— linked control of the course of <i>M. leprae</i> infections. de Vries, R. R. P., <i>et al.</i> , . . . .(A)	260
— system, Analysis of the immunogenetic background of Japanese leprosy patients by. Izumi, S., <i>et al.</i> . . . . .(A)	562
tuberculoid leprosy and . . . in Japanese. Miyanga, K., <i>et al.</i> . . . . .(A)	404

**Hypersensitivity,**

- age-specific tuberculin, The pattern of, in two groups of South African schoolchildren. Gatner, E. M. S. and Rubinstein, E. ....(A) 134
- and immunity in the spectrum of leprosy, The dissociation of. RIDLEY, D. S. ....(C) 363
- DTH response to normal mice through infusion of splenic cells of such vaccinated mice, Inhibition of foot pad multiplication of *M. leprae* precursor coccoid organisms and passive transfer of. Bhide, M. B., *et al.* ....(A) 400
- delayed . . . after BCG in preschool children in relation to their nutritional status (India). Seth, V., *et al.* ....(A) 268
- , —, (DH) inducing antigen(s) from lepromin, Attempts for purification of specific skin. Assessment of Dharmendra antigen. V. Sengupta, U., *et al.* ....(A) 552
- delayed-type, Antigenic analysis of *M. leprae* in lepromins with reference to. Sengupta, U., *et al.* ....(A) 594
- pharmacologically active mediators of . . . reactions in the blood of lepromatous patients with erythema nodosum leprosum. Kaha, K. and Lahiri, S. C. ....(A) 252
- repeated delayed-type . . . reaction against *Mycobacterium lepraemurium* antigens at the infection site do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. ....(A) 363

**IgA,**

- and IgM antibodies against *Mycobacterium leprae* in cord sera and in patients with leprosy; an indicator of intrauterine infection in leprosy. Melsom, R., *et al.* ....(A) 397
- nephropathy in leprosy (Letter to the Editor). Valles, M., *et al.* ....(A) 539

**IgE,**

- circulating immunoglobulin levels in patients with pulmonary tuberculosis with special reference to. Gatner, E. M. S., *et al.* ....(A) 566
- in leprosy. NUTI, M., *et al.* ....(C) 217

**IgM,**

- IgA and . . . antibodies against *Mycobacterium leprae* in cord sera and in patients with leprosy; an indicator of intrauterine infection in leprosy. Melsom, R., *et al.* ..(A) 397

**IMMLEP,**

- Annual report of . . . and THELEP, 1980–1981. ....(N) 233
- IMMLEP Steering Committee meetings. ....(N) 516
- testing of purified armadillo-derived *Mycobacterium leprae* in man. ....(N) 378

**Immune complexes,**

- and complement in leprosy. Geniteau, M., *et al.* ....(A) 394
- circulating, in normal blood donors of three races. Pudifin, D. J. and Duursma, J. ....(A) 251
- in leprosy patients from an endemic and nonendemic area and a longitudinal study of the relationship between complement breakdown products and the clinical activity of erythema nodosum leprosum. Valentijn, R. M., *et al.* ....(A) 399
- in the spectrum of tuberculosis. Brostoff, J., *et al.* ....(A) 134

**Immune responses,**

- and immunostimulation in tuberculosis therapy. Gatner, E. M. S. and Anderson, R. ..(A) 566
- high immune and low resistance granulomas in leprosy, immunoperoxidase study of immunological factors in. Ridley, M. J. and Russell, D. ....(A) 551
- humoral, Subcutaneous amyloid deposits and; a family study of leprosy. WANGEL, A. G., *et al.* ....(O) 47
- immune status in pulmonary tuberculosis patients. Mirza, Z. ....(A) 567
- strain difference of, in mice infected with *Mycobacterium lepraemurium*. Hirooka, Y., *et al.* ....(A) 558

**Immunity,**

- cell-mediated, effect of body temperature and . . . on the growth of *Mycobacterium marinum* and *Mycobacterium leprae* in mice. Lancaster, R. D., *et al.* ....(A) 556
- , in lepromatous leprosy using HLA-D-identical siblings, Studies on the defect in. Absence of circulating suppressor cells and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., *et al.* ....(A) 553
- , of guinea pigs examined by rabbit red blood cell rosette formation method, On the immunodepressive effect of rifampicin (RFP) on. Gidoh, M. and Tsutsumi, S. ..(A) 386

cell-mediated and humoral, consequence of alterations of . . . during pregnancy and lactation. Pregnancy and leprosy. DUNCAN, M. E., <i>et al.</i> . . . . .(O)	425
humoral, in leprosy: immunoglobulin G and M antibody responses to <i>Mycobacterium leprae</i> in relation to various disease patterns. Touw, J., <i>et al.</i> . . . . .(A)	553
hypersensitivity and . . . in the spectrum of leprosy, dissociation of. RIDLEY, D. S. . . .(C)	363
macrophages and protective, in <i>Mycobacterium lepraemurium</i> infections in a 'resistant' (C57Bl) and a 'susceptible' (BALB/c) mouse strain. Preston, P. M. . . . .(A)	560
specific, in protecting against leprosy, relative importance of. Bryceson, A. . . . .(A)	258
<b>Immunoglobulin(s),</b>	
circulating . . . levels in patients with pulmonary tuberculosis with special reference to IgE. Gartner, E. M. S., <i>et al.</i> . . . . .(A)	566
— class specific antibodies in <i>M. leprae</i> in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy. Melsom, R., <i>et al.</i> . . . . .(A)	397
— G and M antibody responses to <i>Mycobacterium leprae</i> in relation to various disease patterns. Humoral immunity in leprosy. Touw, J., <i>et al.</i> . . . . .(A)	553
salivary, in leprosy. GUPTA, S. C., <i>et al.</i> . . . . .(C)	219
serum, and autoantibodies during and after erythema nodosum leprosum (ENL). SHARMA, V. K., <i>et al.</i> . . . . .(O)	159
<b>Immunology,</b>	
leprosy. Cabrini, J. M., <i>et al.</i> . . . . .(A)	249
of filariasis. . . . .(A)	135
of leprosy, mycobacteriologist's view of. Stanford, J. L. . . . .(A)	398
—, speculations on the leprosy spectrum. Sasonetti, P. and Lagrange, P. H. . . . .(A)	131
<b>Immunoperoxidase,</b>	
— study of immunological factors in high immune and low resistance granulomas in leprosy. Ridley, M. J. and Russell, D. . . . .(A)	551
—, —, —, —, in skin lesions across the spectrum of leprosy. RIDLEY, M. J., <i>et al.</i> . . .(O)	11
<b>Immunotherapy,</b>	
of leprosy. Leon, A. P. . . . .(A)	130
with a mixture of <i>Mycobacterium leprae</i> and BCG in different forms of leprosy and in Mitsuda-negative contacts. CONVIT, J., <i>et al.</i> . . . . .(O)	415
<b>Indeterminate leprosy,</b>	
a valid clinical concept. BROWNE, S. G. . . . .(C)	221
histology of. LIU TZE-CHUN, <i>et al.</i> . . . . .(O)	172
histopathology of primary. Liu Zijun, <i>et al.</i> . . . . .(A)	550
how . . . got its name. Arnold, H. L. . . . .(A)	243
reply to Dr. Browne's Letter to the Editor. PETTIT, JOHN H. S. . . . .(C)	224
specific skin test responses in children of patients with . . . tuberculoid leprosy, and lepromatous leprosy. Gimenez, M. and Morini, J. C. . . . .(A)	395
<b>India,</b>	
age at onset of leprosy (analytic data from northern India). Sehgal, V. N., <i>et al.</i> . . . .(A)	563
Anti-leprosy Day 1982. . . . .(N)	236
bancroftian filariasis in East Godavari district (A.P.), General morbidity, leprosy, scabies and common cold in association with. Rao, C. K., <i>et al.</i> . . . . .(A)	545
BCG in preschool children, Delayed hypersensitivity after, in relation to their nutritional status. Seth, V., <i>et al.</i> . . . . .(A)	268
Birla Smarak Kosh award for Professor Talwar. . . . .(N)	230
Bombay, ILO/DANIDA Asian regional seminar on vocational rehabilitation. . . . .(N)	227
Bombay Leprosy Project; Report of Activities 1976–1981. . . . .(N)	514
Dr. B. C. Roy National Award to Dr. A. J. Selvapandjan. . . . .(N)	231
epidemiological situation of leprosy in. Christian, M. . . . .(A)	259
Green Pastures Leprosy Hospital—Nepal, Ocular findings in leprosy: Results of a survey in. Brandt, F., <i>et al.</i> . . . . .(A)	128
HLA and sporadic tuberculoid leprosy: a population study in Maharashtra. van Eden, W., <i>et al.</i> . . . . .(A)	405

ICMR awards for 17 scientists. ....(N)	230
illness and service utilization behaviours of leprosy patients. Kumar, A. and Anbalagan, M. ....(A)	564
immunoepidemiological studies on subclinical infection in leprosy in household contacts in; a preliminary report. Bharadwaj, V. P., <i>et al.</i> ....(A)	600
Indian Association of Leprologists, new officers of. ....(N)	124
Indian Council of Medical Research, <i>Annual Report of the Director-General 1980-81.</i> Ramalingaswami, V. ....(B)	527
leprosy among urban and rural schoolchildren of Andhra Pradesh, study of. Rao, P. S. S., <i>et al.</i> ....(A)	563
—, cases in the Gandhi Kusth Ashram, Jodhpur (Rajasthan), sociological study of. Vyas, G. K., <i>et al.</i> ....(A)	566
—, control: renewed effort by the government of. Saxena, M. L. and Johnsen, D. O. ....(N)	375
Malunga (Nepal), report of a survey in. Ocular findings in leprosy patients. Brandt, F. and Malla, O. K. ....(A)	128
Nepal Leprosy Relief Association. Shrestha, K. B. ....(N)	123
Oragadam Village, Multi-drug regimen pilot project. ....(N)	231
Padma Bhushan honor to Dr. J. M. Mehta. ....(N)	230
Prime Minister Gandhi addresses the American Association for the Advancement of Science. ....(N)	522
prizes for medical students. ....(N)	236
Tamil Nadu, Leprosy in. ....(A)	538
XII International Leprosy Congress. ....(N)	515
<i>Urban Leprosy Control.</i> ....(B)	383
Workshop of National Leprosy Control Programme of Varansi Region. ....(N)	230
<b>Indonesia,</b>	
leprosy control in Surabaya. Soendijojo, A., <i>et al.</i> ....(A)	405
<b>Inoculation,</b>	
animal, <i>In vitro</i> cultivation of <i>Mycobacterium lepraemurium</i> and its identification by. Ishaque, M. ....(A)	132
experimental animals inoculated with <i>M. leprae</i> , comparative study of the nerve lesions of. Nishiura, M. and Fukunishi, Y. ....(A)	589
intra-upper lip . . . method, NFS/N nude mouse as a new model using. The nude mouse as an experimental lepromatous model (continued). Nakamura, K. and Yogi, Y. ....(A)	585
mouse food pad, brief review of experiences with short-term clinical trials monitored by. Shepard, C. C. ....(A)	245
of <i>Mycobacterium leprae</i> into the 'rhino mouse'. Kohsaka, K., <i>et al.</i> ....(A)	583
<b>INTERNATIONAL JOURNAL OF LEPROSY (IJL),</b>	
German Leprosy Relief Association congratulates. Kober, H. ....(N)	513
1981 JOURNAL; a continuing perspective. HASTINGS, R. C. ....(E)	102
requests news from national leprosy organizations. Lechat, M. F. ....(N)	122
reviewers, list of ....(—)	604
statement of financial condition ....(—)	410
statement of ownership, management and circulation ....(—)	618
<b>International Leprosy Association (ILA),</b>	
fiftieth renewal of membership in . . . by Dr. S. Takashima. ....(N)	376
organization and membership ....(—)	605
<b>International Leprosy Congress, XII,</b>	
first notice. Brown, S. G. ....(N)	120
revised dates and program ....(N)	515
<b>Isoniazid (INH),</b>	
combination of . . . prothionamide and dapsone against <i>Mycobacterium leprae</i> and some other mycobacteria, Activity of. Pattyn, S. R., <i>et al.</i> ....(A)	387
in the treatment of experimental mouse tuberculosis, role of low dosage prothionamide with and without 4,4'-diaminodiphenyl sulphone for use with. Grosset, J., <i>et al.</i> ....(A)	407

- resistance to rifampicin and . . . in strains of *Mycobacterium tuberculosis*. Siddiqi, S. H., *et al.* . . . . .(A) 409
- Italy,**  
Leonard Wood Memorial Scientific Symposium, Bellagio, 2–4 June 1982. . . . .(N) 521
- Japan,**  
Dr. S. Takashima, Fiftieth renewal of membership in ILA. . . . .(N) 376  
Japanese leprosy patients, Analysis of the immunogenetic background of, by the HLA system. Izumi, S., *et al.* . . . . .(A) 562  
Sasakawa Memorial Health Foundation (SMHF) reference and health learning materials. . . . .(N) 231  
tuberculoid leprosy and HLA in. Miyanga, K., *et al.* . . . . .(A) 404  
U.S.-. . . Cooperative Medical Science Program, Seventeenth Joint Leprosy Research Conference, Sendai, Japan, 25–27 July 1982. . . . .(—) 569
- Karat, Aaron Benedict Abiel,**  
obituary. Brand, P. W. . . . .(Ob) 359
- Kidney(s)**  
IgA nephropathy in leprosy. (Letter to the Editor). Valles, M., *et al.* . . . . .(A) 539
- Kinetics,**  
bacterial growth, of “M. lufu” in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy against *M. leprae*. SEYDEL, J. K. and WEMPE, E. G. . . . .(O) 20  
pre-S-phase cell cycle, of mitogen-stimulated normal human lymphocytes, Serum inhibitory factor in lepromatous leprosy; its effect on. Potts, R. C., *et al.* . . . . .(A) 251
- Korea,**  
DDS-resistant leprosy in. Kim, D. . . . .(A) 386  
Miss Grace Bennett retires from The Leprosy Mission (TLM) in. . . . .(N) 376
- Kveim test,**  
in leprosy; a clinical and histopathological evaluation. Kaur, S., *et al.* . . . . .(A) 246
- Lactation,**  
breast secretion of lactating mothers with lepromatous leprosy, Decreased cellular and humoral anti-infective factors in. Saha, K., *et al.* . . . . .(A) 252  
neuritis in pregnancy and. DUNCAN, M. E. and PEARSON, J. M. H. . . . .(O) 31  
pregnancy and, consequence of alterations of cell-mediated and humoral immunity during: pregnancy and leprosy. DUNCAN, M. E., *et al.* . . . . .(O) 425
- Lactic/Lactate,**  
blood . . . and pyruvic acids in leprosy, effect of dapsone on. SINHA, S. N., *et al.* . . .(O) 468  
— dehydrogenase in sera of patients with leprosy, anomalous isoenzymes of. Saoji, A. M. and Kelkar, S. S. . . . .(A) 557  
—, —, isoenzymes in the sera of hanseniasis patients. Garcia, R., *et al.* . . . . .(A) 542  
serum . . . dehydrogenase isoenzyme patterns in leprosy, Qualitative studies of. Saoji, A. M. and Kelkar, S. S. . . . .(A) 247
- Lamprene®,**  
ILEP information on side-effects from clofazimine. . . . .(N) 233
- Lara, Casmiro B.,**  
Obituary. Jose, F. A., Jr. . . . .(Ob) 213
- Latin America,**  
epidemiological situation in the Americas. Motta, C. P. . . . .(A) 263  
Iberian Latin American Congress of Dermatology . . . . .(N) 119
- Leishmaniasis,**  
experimental cutaneous, Disseminated . . . in genetically susceptible and resistant mice. Scott, P. A. and Farrell, J. P. . . . .(A) 409

**Leonard Wood Memorial,**

- Laboratory/Cebu/Philippines, Third Standardization Workshop for Joint Chemotherapy Trials. Reich, C. V. . . . .(N) 124
- Scientific Symposium, Bellagio, Italy, 2-4 June 1982. . . . .(N) 521
- Leprosy Scientific Memoranda to resume in fall 1982. . . . .(N) 522

**Leproma,**

- histoid, Observations on ultrastructure of. LIU JIHE, *et al.* . . . . .(O) 471
- histopathological change of, after BCG and levamisole injection in lepromatous leprosy patients, study on. Kim, D. . . . .(A) 396
- Mycobacterial strains adapted to cultures separated from human, Identifying characteristics vis-a-vis *Mycobacterium leprae*. Coudert, J., *et al.* . . . . .(A) 554
- rat or mice, are not the aetiologic agents of murine leprosy, Mycobacteria of *Mycobacterium scrofulaceum* type isolated from. Ishaque, M. . . . .(A) 555

**Lepromatous leprosy,**

- active, Reversion of the downhill course of, by repeated transfusions of fresh blood; donated by healthy but lepromin positive patients. Saha, K., *et al.* . . . . .(A) 552
- BCG and levamisole injection in . . . patients, study on histopathological change of leproma after. Kim, D. . . . .(A) 396
- blood of . . . patients with erythema nodosum leprosum, Pharmacologically active mediators of hypersensitivity reactions in. Saha, K. and Lahiri, S. C. . . . .(A) 252
- breast secretions of lactating mothers with . . . , Decreased cellular and humoral anti-infective factors in. Saha, K., *et al.* . . . . .(A) 252
- cell-mediated immunity in, Studies on the defect in, using HLA-D-identical siblings. Absence of circulating suppressor cells and evidence that the defect is in the T lymphocyte rather than the monocyte population. Stoner, G. L., *et al.* . . . . .(A) 553
- children of patients with indeterminate leprosy, tuberculoid leprosy, and . . . , Specific skin test responses in. Gimenez, M. and Morini, J. C. . . . .(A) 395
- class specific anti-*Mycobacterium leprae* antibody assay in . . . (BL-LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et al.* . . . . .(O) 271
- clofazimine alone or combined with dapsone on neutrophil and lymphocyte functions in normal individuals and patients with, Effects of. Van Rensburg, C. E., *et al.* . . .(A) 539
- dermal infiltrate in, morphology of bacilli at different levels of. GIRDHAR, B. K. and McDUGALL, A. C. . . . .(O) 477
- diffuse, in Costa Rica. Castro-Coto, A. and Hidalgo-Hidalgo, H. . . . .(A) 388
- human testis in patients with, Immunoreactivity *in vitro* to. Wall, J. R. and Walters, B. A. J. . . . .(A) 255
- In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. Effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, tuberculin purified derivative and non-mycobacterial stimulants. REITAN, L. J., *et al.* . . . . .(O) 455
- leucocytes from . . . patients with hapten modified *M. leprae*, Improved leucocyte migration inhibition response of. Fotedar, A., *et al.* . . . . .(A) 547
- Lucio phenomenon in a case of lepromatous paucinodular leprosy. Peyri, L., *et al.* . . .(A) 544
- lymphocyte transformation test (LTT) by phytohemagglutinin, lepromin and *M. leprae* in . . . patients, negatives and positives: prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* . . . . .(A) 548
- M. leprae* isolated from the lymph of a . . . patient by means of the freeze-fracture technique, Studies on. Sanabria Negrin, J. G., *et al.* . . . . .(A) 556
- mouse as an experimental . . . model, hereditarily athymic asplenic (LASAT), (continued): role of the spleen in the formation of the lepromatoid lesions. Nakamura, K. and Yogi, Y. . . . .(A) 586
- , —, —, —, nude (continued): the NFS/N nude mouse as a new model using the intra-upper lip inoculation method. Nakamura, K. and Yogi, Y. . . . .(A) 585
- natural resistance against tetanus, in patients with. Saha, K., *et al.* . . . . .(A) 392
- nerve abscess in. Malaviya, G. N., *et al.* . . . . .(A) 543
- nose in, bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time. BARTON, R. P. E., *et al.* . . . . .(O) 58
- ocular lesions in. Chovet, M., *et al.* . . . . .(A) 128
- proteins in, Electrophoretic pattern of. Baji, P. S., *et al.* . . . . .(A) 540

- rat as an experimental . . . model, nude (continued): effects of carrageenans, splenectomy, and treatment with thymus cells. Nakamura, K. and Yogi, Y. . . . .(A) 587
- rifampicin, Once-monthly, plus daily dapsone in initial treatment of. Yawalkar, S. J., *et al.* . . . . .(A) 540
- serological and immunohistological studies on. Kano, K., *et al.* . . . . .(A) 550
- serum inhibitory factor in, its effect of the pre-S-phase cell cycle kinetics of mitogen-stimulated normal human lymphocytes. Potts, R. C., *et al.* . . . . .(A) 251
- small bowel in, Structure and function of. KUMAR, N., *et al.* . . . . .(O) 148
- Lepromin,**
- antigenic analysis of *M. leprae* in . . . with reference to the delayed type of hypersensitivity. Sengupta, U., *et al.* . . . . .(A) 594
- cytoplasmic mycobacterial antigens on the late reactivity to, Double blind trial on the effect of certain soluble. HADDAD, N., *et al.* . . . . .(O) 325
- healthy but . . . positive patients, Reversion of the downhill course of active lepromatous leprosy by repeated transfusions of fresh blood donated by. Saha, K., *et al.* . . .(A) 552
- integral . . . and . . . treated with ultrasound, study comparing the interdermal reactions following, in normal individuals. Karazawa, E. H., *et al.* . . . . .(A) 550
- test, Type 1 lepra reaction induced by; a case report. Dong Li-Wen, *et al.* . . . . .(A) 541
- lymphocyte transformation test (LTT) by phytohemagglutinin, . . . and *M. leprae* in lepromatous leprosy patients, negatives and positives: prognostic value compared with that of . . . . Guimaraes Pagnano, P. M., *et al.* . . . . .(A) 548
- normal bacillary, Cutaneous response to, incubated with sera from patients with distinct clinical forms of leprosy. Corona, C. J. J., *et al.* . . . . .(A) 249
- post . . . scar, Studies on. Tarabini-Castellani, G., *et al.* . . . . .(A) 253
- purification of specific skin delayed hypersensitivity (DH) inducing antigens from . . . ., Attempts for. Assessment of Dharmendra antigen. V. Sengupta, U., *et al.* . . .(A) 552
- skin test response to *M. leprae* precursor coccoid organisms in a high leprosy endemic area as compared to. Chatterjee, B. R. . . . . .(A) 400
- tissue response to, index of susceptibility of the armadillo to *M. leprae* infection; a preliminary report. Job, C. K., *et al.* . . . . .(O) 177
- whole human and armadillo . . . in 50 leprosy patients, comparative study. Mitsuda reaction. Zambrano, M. T., *et al.* . . . . .(A) 129
- Leprosy,**
- Abu Ali Ibn-Sina (Avicenna) on. Abdullaev, A. H. and Sharafiddinov, T. A. . . . .(A) 534
- An Atlas of Leprosy.* Guinto, R. S., *et al.* . . . . .(B) 239
- information sources of . . . with particular reference to developing countries. Dorrington, L. . . . . .(A) 385
- Binford, C. H., *et al.* . . . . .(A) 385
- ; a disease of the heart. Crawshaw, R. . . . . .(A) 534
- a zoonosis. Walsh, G. P., *et al.* . . . . .(A) 267
- quality of service to . . . patients, Factors influencing. McDougall, A. C. . . . .(E) 355
- Lesions,**
- dermal, of leprosy, *in situ* characteristics of mononuclear cell infiltrates in. GUPTA, S. K., *et al.* . . . . .(O) 297
- histopathological features of leprosy . . . in the skin and peripheral nerve, Discrepancy in. Report of a preliminary study. Srinivasan, J., *et al.* . . . . .(A) 553
- human and murine leprosy, egg-yolk reaction produced by, and its cultural significance on primary isolation. Koseki, Y., *et al.* . . . . .(A) 577
- , leprosy, Base compositions and homologies of deoxyribonucleic acids of corynebacteria isolated from, and of related microorganisms. Danhaive, P., *et al.* . . . . .(A) 256
- , —, Chemical identification of some cell wall components of microorganisms isolated from. Janczura, E., *et al.* . . . . .(A) 401
- , —, skin, Immunohistopathologic study of  $\beta$ -glucuronidase and lysozyme in. Matsuo, E., *et al.* . . . . .(A) 599
- hypo-pigmented, in children, study of. Dutta, R. K. and Murthy, N. . . . .(A) 389
- lepromatoid, role of the spleen in the formation of the. Hereditarily athymic asplenic (LASAT) mouse as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. . . . .(A) 586

nerve, of experimental animals inoculated with <i>M. leprae</i> , Comparative study of.		
Nishiura, M. and Fukunishi, Y. ....(A)		589
ocular, in lepromatous leprosy. Chovet, M., <i>et al.</i> ....(A)		128
—, in leprosy. Reddy, S. C., <i>et al.</i> ....(A)		247
orofacial, of leprosy, Clinical evaluation of. Prabhu, S. R. and Daftary, D. K. ....(A)		545
skin, across the spectrum of leprosy, immunoperoxidase study of immunological factors in. RIDLEY, M. J., <i>et al.</i> ....(O)		11
ultrastructures of cells in . . . of lepromatous and tuberculoid leprosy. Liu Zijun, <i>et al.</i> ..(A)		551
visceral, Dimorphous hanseniasis with outbreaks of hansenic reaction and. ....(A)		246
<b>Leukocytes,</b>		
improved leucocyte migration inhibition response of, from lepromatous leprosy patients with hapten modified <i>M. leprae</i> . Fotedar, A., <i>et al.</i> ....(A)		547
leukocytoclastic vasculitis. Mackel, S. E. and Jordan, R. E. ....(A)		407
polymorphonuclear . . . (PMN) chemotaxis, Thalidomide does not affect. Miyachi, Y. and Ozaki, M. ....(A)		387
<b>Levamisole,</b>		
BCG and . . . injection in lepromatous leprosy patients, study on histopathological change of leproma after. Kim, D. ....(A)		396
<b>Lipid(s),</b>		
— composition of <i>Mycobacterium phlei</i> , Effect of growth temperature and exogenous fatty acids on. Taneja, R., <i>et al.</i> ....(A)		567
lipidic constituents of <i>Mycobacterium leprae</i> isolated from experimentally infected armadillo. Asselineau, C., <i>et al.</i> ....(A)		131
of <i>Mycobacterium gordonae</i> in comparison with those of <i>M. leprae</i> and of some other scotochromogenic mycobacteria, Studies on. Daffe, M., <i>et al.</i> ....(A)		400
<b>Liposome,</b>		
stimulation of growth of <i>Mycobacterium lepraemurium</i> in cell-free liquid medium by aspartic acid, sucrose, . . . , thymidine, and deoxyuridine (NDLASU medium). Nakamura, M. ....(A)		578
<b>Liver(s),</b>		
antitoxic function of, in patients with leprosy, Radioisotope detection of. Kharatyan, A. M. and Kenzhebaev, A. Y. ....(A)		396
armadillo, infected with <i>Mycobacterium leprae</i> , Isolation of fastidiously growing mycobacteria from. PORTAELS, F. and PATTYN, S. R. ....(C)		370
—, Superoxide dismutase, peroxidatic activity and catalase in <i>Mycobacterium leprae</i> purified with. Wheeler, P. R. and Gregory, D. ....(A)		557
in leprosy. II. Histopathological changes. Robins, K., <i>et al.</i> ....(A)		398
<b>Lucio leprosy,</b>		
Lucio phenomenon. Compa, F. V., <i>et al.</i> ....(A)		389
—, —, and diffuse lepromatous leprosy pure and primitive in a nonleprosy endemic area. Rea, T. H. ....(A)		392
—, —, in a case of lepromatous paucinodular leprosy. Peyri, L., <i>et al.</i> ....(A)		544
Lucio's leprosy. Compa, F. V., <i>et al.</i> ....(A)		389
spectrum of the necrotizing lepra reactions. (Allergic cutaneous vasculitis; Lucio phenomenon.) A proposed intermediate lepra reaction. Peyri, L., <i>et al.</i> ....(A)		545
<b>Lupus vulgaris,</b>		
BCG vaccine-induced. Izumi, A. K. and Matsunaga, J. ....(A)		407
<b>Lymph node(s),</b>		
distant, of mice, Response in, to infection in the hind foot pad with <i>Mycobacterium marinum</i> . Mor, N., <i>et al.</i> ....(A)		559
immunologic functions of, in leprosy, Preliminary study on. Gu Zhijie, <i>et al.</i> ....(A)		548
popliteal, Response in the hind foot pad and, of C57Bl mice to infection with <i>Mycobacterium marinum</i> . Mor, N., <i>et al.</i> ....(A)		559

**Lymphocyte(s),**

- antigen stimulated human . . . by histamine, Specific modulation of. Nanda, N. K. and Nath, I. . . . .(A) 551
- in vitro* . . . stimulation in patients with lepromatous and borderline tuberculoid leprosy. Effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, tuberculin purified protein derivative and non-mycobacterial stimulants. REITAN, L. J., *et al.* . . . . .(O) 455
- , —, stimulation using a purified antigen of *M. leprae* and tuberculin PPD. Closs, O. and Reitan, L. J. . . . .(A) 259
- , —, stimulation of . . . in leprosy patients, healthy contacts of leprosy patients, and subjects not exposed to leprosy. Closs, O., *et al.* . . . . .(A) 547
- macrophages versus . . . in leprosy. BEIGUELMAN, B. . . . .(E) 501
- mitogen-stimulated human, Serum inhibitory factor in lepromatous leprosy; its effect on the pre-S-phase cell cycle, kinetics of. Potts, R. C., *et al.* . . . . .(A) 251
- neutrophil and . . . functions in normal individuals and patients with lepromatous leprosy, Effects of clofazimine alone or combined with dapsone on. Van Rensburg, C. E., *et al.* . . . . .(A) 539
- peripheral blood, Prostaglandin-dependent regulation of the *in vitro* proliferative response to mycobacterial antigens of, from normal donors and from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* . . . . .(A) 129
- , —, T and B . . . in leprosy, study of. Hee Chul Eun, *et al.* . . . . .(A) 549
- PHA induced blastoid transformation of . . . in leprosy contacts. Hardas, U. D. and Jalgaonkar, S. V. . . . .(A) 536
- phytohaemagglutinin (PHA)-induced . . . transformation, *in vitro* effect of DDS on. Ghei, S. K., *et al.* . . . . .(A) 395
- T . . . , Absence of circulating suppressor cells and evidence that the defect is in, rather than the monocyte population. Studies on the defect in cell-mediated immunity in lepromatous leprosy using HLA-D-identical siblings. Stoner, G. L., *et al.* . . . . .(A) 553
- , —, and acid non-specific esterase activity in leprosy patients, Investigation of. Qiang Nengxian, *et al.* . . . . .(A) 251
- , —, Hypothesis: erythema nodosum leprosum is precipitated by an imbalance of. Mshana, R. N. . . . .(A) 251
- , —, subsets in leprosy granulomas, *In situ* characterization of. MODLIN, R. L., *et al.* . . . . .(C) 361
- thymus dependent, in leprosy. I. T . . . subpopulations defined by monoclonal antibodies. MSHANA, R. N., *et al.* . . . . .(O) 291
- transformation of, from normal individuals, *in vitro* and *in vivo* effects of clofazimine on the motility of neutrophils and. Gatner, E. M. S., *et al.* . . . . .(A) 386

**Lymphocyte transformation test (LTT),**

- by phytohemagglutinin, lepromin and *M. leprae* in lepromatous leprosy patients, negatives and positives; prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* . . . . .(A) 548
- in leprosy with special reference to its use in epidemiology. Bjune, G. . . . .(A) 258

**Lysozyme,**

- $\beta$ -glucuronidase and . . . in human leprosy skin lesions, Immunohistopathologic study of. Matsuo, E., *et al.* . . . . .(A) 599
- serum . . . (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., *et al.* . . . . .(A) 246
- tear, in lepromatous leprosy. SEN, D. K. and SARIN, G. S. . . . .(O) 322

**Macrophage(s),**

- and protective immunity in *Mycobacterium lepraemurium* infections in a 'resistant' (C57Bl) and a 'susceptible' (BALB/c) mouse strain. Preston, P. M. . . . .(A) 560
- differentiated human, Incorporation of <sup>3</sup>H-thymidine in *Mycobacterium leprae* within. Prasad, H. K. and Nath, I. . . . .(A) 132
- human, effect of *M. leprae* on phagosome-lysosome fusion in. Scollard, D. M. and Gardner, I. D. . . . .(A) 596

— culture method, Rapid, for detection of dapsone-resistant <i>Mycobacterium leprae</i> . Nath, I., <i>et al.</i> . . . . .(A)	244
— cultures, <i>In vitro</i> growth of <i>Mycobacterium lepraemurium</i> under the influence of. Matsuo, Y. and Tatsukawa, H. . . . .(A)	401
murine peritoneal, effect of the infection with <i>Mycobacterium lepraemurium</i> on the level of diverse hydrolytic lysosomal enzymes of. Phagocytosis in leprosy. 5. Ro- JAS-ESPINOSA, O., <i>et al.</i> . . . . .(O)	306
of nude mice, Ultrastructural features of the multiplication of human and murine lep- rosy bacilli in. FUKUNISHI, Y., <i>et al.</i> . . . . .(O)	68
versus lymphocytes in leprosy. BEIGUELMAN, B. . . . .(E)	501
<b>Macular leprosy,</b> macular indeterminate form of leprosy. Strobel, M., <i>et al.</i> . . . . .(A)	393
<b>Madagascar,</b> ocular disease in leprosy in, Contribution to the study of. Andriantsoa-Rasoavelono- ro, V., <i>et al.</i> . . . . .(A)	127
<b>Malaysia,</b> Kuala Lumpur, Fourth International Workshop on Leprosy Control in Asia, site of. Lechat, M. F. . . . .(N)	515
—, —, meeting on social and economic aspects of leprosy (UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases) . . . . .(N)	376
<b>Mali,</b> Paraclinical study of onchocerciasis in a leprosy and nonleprosy population. Penchier, L., <i>et al.</i> , . . . . .(A)	392
<b>Metabolism,</b> antileprosy drugs and their main metabolites in serum by high performance liquid chromatography, Determination of three main. Gidoh, M., <i>et al.</i> . . . . .(A)	244
cholesterol, Indirect assay of beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients; a further probe into. Kannan, K. B., <i>et al.</i> . . . . .(A)	542
differential . . . of fatty acid by mycobacteria, Radiometric measurement of. CAMAR- GO, E. E., <i>et al.</i> . . . . .(O)	200
— activity of purified suspensions of <i>Mycobacterium leprae</i> , Preliminary studies of. Khanolkar, S. R. . . . .(A)	401
new urinary metabolite of clofazimine in leprosy patients. Feng, P. C. C., <i>et al.</i> . . . . .(A)	536
of clofazimine in leprosy patients. Feng, P. C. C., <i>et al.</i> . . . . .(A)	385
<b>Mexico,</b> endemic behavior of leprosy in, during 1980. . . . .(A)	403
Mexican Association of Action Against Leprosy, annual meeting of. Latapi, F. . . . .(N)	516
Mexican Leprosy Society meeting in Zacatecas. . . . .(N)	516
<b>Mice,</b> bacillary multiplication in C3H . . . . . Repeated delayed-type hypersensitivity reaction against <i>Mycobacterium lepraemurium</i> antigens at the infection site do not affect. Løvik, M. and Closs, O. . . . .(A)	397
dapsone in protein deficiency, Disposition of; an experimental study in . . . Venkate- san, K., <i>et al.</i> . . . . .(A)	540
disseminated leishmaniasis in genetically susceptible and resistant . . . . . Experimental cutaneous leishmaniasis. Scott, P. A. and Farrell, J. P. . . . .(A)	409
distant lymph nodes of, Response in, to infection in the hind foot pad with <i>Mycobac- terium marinum</i> . Mor, N., <i>et al.</i> . . . . .(A)	559
experimental infection with <i>Mycobacterium lepraemurium</i> in the CBA/J . . . . . Effects of preimmunization on the evolution of the disease. Corona, C. J. J., <i>et al.</i> . . . . .(A)	402
hairless, ( <i>Mus musculus</i> ), Experimental leprosy with <i>Mycobacterium lepraemurium</i> in. Packchianian, E., <i>et al.</i> . . . . .(A)	560
hereditarily athymic asplenic (LASAT) mouse as an experimental lepromatous lepro- sy model (continued): role of the spleen in the formation of the lepromatoid le- sions. Nakamura, K. and Yogi, Y. . . . .(A)	586
hind foot pad and popliteal lymph node of C57Bl . . . . . to infection with <i>Mycobacte- rium marinum</i> , Response in. Mor, N., <i>et al.</i> . . . . .(A)	559

- immune responses in, infected with *Mycobacterium lepraemurium*, Strain difference of. Hirooka, Y., *et al.* . . . . .(A) 558
- inhibition of foot pad multiplication of *M. leprae* precursor coccoid organism and passive transfer of DTH response to normal . . . through infusion of splenic cells of such vaccinated . . . Bhide, M. B., *et al.* . . . . .(A) 400
- intraperitoneal vaccination against challenge in the foot pad with *Mycobacterium marinum*, Protection of . . . by. Ng, H., *et al.* . . . . .(A) 560
- M. leprae* in mouse foot pad, effect of deoxy fructo serotonin (DFS) on the multiplication of. Balakrishnan, S., *et al.* . . . . .(A) 535
- infected with *Mycobacterium lepraemurium*, Antibacterial resistance in. Patel, P. J. . . . .(A) 133
- mouse foot pad experiments with *M. leprae*, comparison of the skin scrape and skin biopsy methods in. Venkataramanaiah, H. N., *et al.* . . . . .(A) 560
- , —, —, inoculation, experiences with short-term clinical trials monitored by, A brief review of. Shepard, C. C. . . . .(A) 245
- , tuberculosis, experimental, electron microscopy study of intra-cellular mycobacteria in. Kanai, K., *et al.* . . . . .(A) 135
- , —, treatment of experimental, role of low dosage prothionamide with and without 4,4'-diaminodiphenyl sulphone for use with isoniazid in. Grosset, J., *et al.* . . . . .(A) 407
- murine leprosy in C3H . . . vaccinated with extracts of *Mycobacterium lepraemurium* in admixture with *Mycobacterium bovis* (BCG), Lack of a sustained protection against. TURCOTTE, R. and LEMIEUX, S. . . . .(O) 494
- mycobacteria of *Mycobacterium scrofulaceum* type isolated from rat or . . . lepromata are not the aetiologic agents of murine leprosy. Ishaque, M. . . . .(A) 555
- Mycobacterium avium* of C3H/H3 . . . Susceptibility to. Kawaguchi, Y., *et al.* . . . . .(A) 558
- , —, of various inbred strains of, Susceptibility to. I. On the cases with intraperitoneal infection. Tanemura, M. . . . .(A) 402
- , —, II. On the cases with subcutaneous infection. Tanemura, M. . . . .(A) 402
- , *leprae* infection in, Effects of *Propionibacterium acnes* treatment on the course of. Krahenbuhl, J. L., *et al.* . . . . .(A) 558
- , *lepraemurium* infection in, lack of correlation between antigen-specific reactions and resistance to. Curtis, J., *et al.* . . . . .(A) 256
- , *marinum* and *Mycobacterium leprae* in, effect of body temperature and cell-mediated immunity on the growth of. Lancaster, R. D., *et al.* . . . . .(A) 556
- pathogenicity in, and the ability of *M. lepraemurium* to grow in tissue culture cells, relationship between. Nomaguchi, H., *et al.* . . . . .(A) 578
- 'resistant' (C56BI) and a 'susceptible' (BALB/c) mouse strain, Macrophages and protective immunity in *Mycobacterium lepraemurium* infections in. Preston, P. M. . . . .(A) 560
- rhino mouse, Inoculation of *Mycobacterium leprae* into. Kohsaka, K., *et al.* . . . . .(A) 583
- sciatic nerve compound action potential *in vitro* in normal and *M. leprae* infected . . . , A study of. Vidyasagar, P. B., *et al.* . . . . .(A) 401
- , nerves in experimental, Nerve damage in leprosy; a teased fibre study of. Bhat, R. and Vaidya, M. C. . . . .(A) 557
- survival of BALB/c . . . after intravenous infection with *Mycobacterium marinum*. Ng, H., *et al.* . . . . .(A) 560
- various mouse strains infected with a large or small dose of murine leprosy bacilli, Mitogen-induced DNA synthesis in. Yamaura, N., *et al.* . . . . .(A) 399
- Mice, nude,**
- as an experimental lepromatous model (continued): the NFS/N . . . as a new model using the intra-upper lip inoculation method. Nakamura, K. and Yogi, Y. . . . .(A) 585
- in studies of leprosy. Colston, M. J. and Kohsaka, K. . . . .(A) 557
- leprosy chemotherapy in, study of. Effect of dapsone (DDS) on . . . experimentally infected with *Mycobacterium leprae*. Yoneda, K., *et al.* . . . . .(A) 582
- macrophages of, Ultrastructural features of the multiplication of human and murine leprosy bacilli in. FUKUNISHI, Y., *et al.* . . . . .(O) 68
- Mitsuda reaction,**
- early (Fernandez) and late . . . in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigen in three double-blind trials, Correlation between. Bechelli, L. M., *et al.* . . . . .(A) 547
- Mitsuda-negative contacts, Immunotherapy with a mixture of *Mycobacterium leprae* and BCG in different forms of leprosy and in. CONVIT, J., *et al.* . . . . .(O) 415

— Comparative study with whole human and armadillo lepromin in 50 leprosy patients. Zambrano, M. T., <i>et al.</i> . . . . .	(A)	129
<b>Monkeys,</b>		
multibacillary leprosy in unaltered hosts, with emphasis on armadillos and . . . Meyers, W. M., <i>et al.</i> . . . . .	(A)	584
<b>Monocytes,</b>		
chemotaxis of, in hanseniasis. AZULAY, R. D. . . . .	(C)	215
<b>Morphology,</b>		
morphologic and biologic properties of diphtheroid organisms (LDC) isolated in leprosy patients. Delville, J., <i>et al.</i> . . . . .	(A)	554
of bacilli at different levels of the dermal infiltrate in lepromatous leprosy. GIRDHAR, B. K. and MCDUGALL, A. C. . . . .	(O)	477
<b>Muramyl dipeptide,</b>		
absence of antibodies to, in patients with tuberculosis or leprosy. Bahr, G. M., <i>et al.</i> . . . .	(A)	394
<b>Murine leprosy,</b>		
aetiologic agents of, Mycobacteria of <i>Mycobacterium scrofulaceum</i> type isolated from rat or mice lepromata are not the. Ishaque, M. . . . .	(A)	555
experimental, Suppressor cells in. Akiyama, T., <i>et al.</i> . . . . .	(A)	595
human and . . . bacilli in macrophages of nude mice, Ultrastructural features of the multiplication of. FUKUNISHI, Y. <i>et al.</i> . . . . .	(O)	68
—, —, —, lesions, egg-yolk reaction produced by, and its cultural significance on primary isolation. Koseki, Y., <i>et al.</i> . . . . .	(A)	577
— bacilli, Mitogen-induced DNA synthesis in various mouse strains infected with a large or small dose of. Yamaura, N., <i>et al.</i> . . . . .	(A)	399
—, —, phospholipid deacylating activities in. Kashiwabara, Y. and Nakagawa, H. . . . .	(A)	588
sustained protection against . . . , Lack of, in C3H mice vaccinated with extracts of <i>Mycobacterium lepraemurium</i> in admixture with <i>Mycobacterium bovis</i> (BCG). TURCOTTE, R. and LEMIEUX, S. . . . .	(O)	494
<b>Muscle(s),</b>		
— reinnervation, Acceleration by isaxonine of; electrophysiological demonstration in leprotic neuropathy. Sebille, A., <i>et al.</i> . . . . .	(A)	565
posterior tibial, Transplantation of, for correcting leprosy foot drop. . . . .	(A)	134
<b>Mycobacteria,</b>		
antigens of, groups of shared or species specific, preliminary investigation of the responsiveness or otherwise of patients and staff of a leprosy hospital to. Stanford, J. L., <i>et al.</i> . . . . .	(A)	253
atypical, drug sensitivity test strategy for. Hejny, J. . . . .	(A)	407
certain soluble cytoplasmic . . . antigens, Double-blind trial on the effect of, on the late reactivity to lepromin. HADDAD, N., <i>et al.</i> . . . . .	(O)	325
combination of isoniazid, prothionamide and dapsone against <i>Mycobacterium leprae</i> and some other . . . , Activity of. Pattyn, S. R., <i>et al.</i> . . . . .	(A)	387
comparison of <i>M. leprae</i> whole organisms with other . . . , Leprosy ELISA antigen coating buffers and antigens. Naka, S. O. and Douglas, J. T. . . . .	(A)	600
immunological studies with sulpholipids of. Khuller, G. K., <i>et al.</i> . . . . .	(A)	567
intra-cellular, in experimental mouse tuberculosis, electron microscopy study of. Kanai, K., <i>et al.</i> . . . . .	(A)	135
isolation of fastidiously growing . . . from armadillo livers infected with <i>Mycobacterium leprae</i> . PORTAELS, F. and PATTYN, S. R. . . . .	(C)	370
mycobacterial antigens in leprosy tissues, Demonstration of. MSHANA, R. N., <i>et al.</i> . . . .	(O)	1
mycobacterial antigens of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy, Prostaglandin-dependent regulation of the <i>in vitro</i> proliferative response to. Bahr, G. M., <i>et al.</i> . . . . .	(A)	129
Nocardia-like . . . isolated from natural habitats in Zaire. Portaels, F., <i>et al.</i> . . . . .	(A)	408
non-mycobacterial stimulants, tuberculin purified protein derivative and; effect of dapsone treatment on the response to <i>Mycobacterium leprae</i> antigens. <i>In vitro</i>		

- lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* .....(O) 455
- of *Mycobacterium scrofulaceum* type isolated from rat or mice lepromata are not the aetiologic agents of murine leprosy. Ishaque, M. ....(A) 555
- radiometric measurement of differential metabolism of fatty acid by. CAMARGO, E., *et al.* .....(O) 200
- scotochromogenic, Studies on the lipids of *Mycobacterium gordonae* in comparison with those of *M. leprae* and of some other. Daffe, M., *et al.* .....(A) 400
- Spontaneous release of mycophages from lysogenic bovine strains. Tageldin, M. H., *et al.* .....(A) 268
- viability of . . . cells, fluorescent staining procedure for determining. KVACH, J. and VERAS, J. R. ....(O) 183
- Mycobacterium avium*,**
- susceptibility of, of various inbred strains of mice. I. On the cases with intraperitoneal infection. Tanemura, M. ....(A) 402
- II. On the cases with subcutaneous infection. Tanemura, M. ....(A) 402
- , to, of C3H/H3 mice. Kawaguchi, Y. *et al.* ....(A) 558
- Mycobacterium bovis*,**
- antigenic diversity of *Mycobacterium tuberculosis* and . . . detected by means of monoclonal antibodies. Coates, A. R. M., *et al.* ....(A) 225
- (BCG), Lack of a sustained protection against murine leprosy in C3H mice vaccinated with extracts of *Mycobacterium lepraemurium* in admixture with. TURCOTTE, R. and LEMIEUX, S. ....(O) 494
- , —, vaccination, Effect of, upon *Mycobacterium lepraemurium* infection. Lefford, M. J., *et al.* ....(A) 133
- Ultrastructural characteristics of . . . BCG and *Mycobacterium leprae*. BINKHUYSEN, F. and DAS, P. K. ....(O) 76
- Mycobacterium chelonae*,**
- identification of, by thin-layer chromatographic analysis of whole-organism methanolytates. Goodfellow, M. and Minnikin, D. E. ....(A) 267
- In vitro* susceptibility of *Mycobacterium fortuitum* and . . . to cefoxitin. Casal, M. and Rodriguez, F. ....(A) 566
- isoelectric focusing studies on. Sparks, J. and Ross, G. W. ....(A) 268
- Mycobacterium fortuitum*,**
- In vitro* susceptibility of . . . and *Mycobacterium chelonae* to cefoxitin. Casal, M. and Rodriguez, F. ....(A) 566
- Mycobacterium gordonae*,**
- lipids of, in comparison with those of *M. leprae* and of some other scotochromogenic mycobacteria, Studies on. Daffe, M., *et al.* .....(A) 400
- Mycobacterium intracellulare*,**
- clofazimine against, Dynamic aspects of the activity of. Gangadharam, P. R., *et al.* . . .(A) 126
- Mycobacterium leprae*,**
- adenosine triphosphate content of, effect of purification procedures. DHOPLE, A. M. and STORRS, E. E. ....(O) 83
- and the host response. Harboe, M. ....(A) 261
- antigenic analysis of, in lepromins with reference to the delayed type of hypersensitivity. Sengupta, U., *et al.* ....(A) 594
- antileprosy drugs on glycolytic processes in rats infected with . . ., influence of. Rezaev, A. A. ....(A) 245
- armadillo-derived, epidemiological evaluation, in Burma, of the skin test reagent LRA6; a cell-free extract from. Part 1. Leprosy patients. SHIELD, M. J., *et al.* . . .(O) 436
- Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. ....(O) 446
- Biochemical correlation of *M. vaccae* with. Dutta, A. K., *et al.* ....(A) 554
- Class specific anti-. . . antibody assay in lepromatous leprosy (BL-LL) patients during the first two to four years of DDS treatment. MELSOM, R., *et al.* ....(O) 271

combined chemotherapy against, model for the development of. Bacterial growth kinetics of "M. lufu" in the presence and absence of various drugs alone and in combination. SEYDEL, J. K. and WEMPE, E. G. ....(O)	20
cultivation of, in cell culture under regulation of redox potential at environment, Attempts at. Matsuo, Y. and Tatsukawa, H. ....(A)	556
—, the neglected priority. KATO, L. ....(C)	368
cycloheximide for cultivating . . . and <i>Mycobacterium lepraemurium</i> in cell culture, Use of. Matsuo, Y. ....(A)	578
dapsone (DDS), Effect of, on nude mice experimentally infected with. The study of leprosy chemotherapy in nude mice. Yoneda, K., <i>et al.</i> ....(A)	582
—, -resistant, Increase in prevalence of leprosy caused by. ....(N)	234
—, -resistant, Rapid macrophage culture method for detection of. Nath, I., <i>et al.</i> ....(A)	244
—, treatment, effect of, on the response to . . . antigens, tuberculin purified protein derivative and non-mycobacterial stimulants. <i>In vitro</i> lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., <i>et al.</i> . . .(O)	455
deoxy fructo serotonin (DFS), Effect of, on the multiplication of . . . in mouse foot pad. Balakrishnan, S., <i>et al.</i> ....(A)	535
diacyl phtioceral in secretions from, Structure and antigenicity of the specific phenolic glycolipid antigens and a related. Hunter, S. W. <i>et al.</i> ....(A)	591
DNA isolated from: genome size, base ratio, and homology with other related bacteria as determined by optical DNA-DNA reassociation. Imaeda, T., <i>et al.</i> ....(A)	400
effect of, on phagosome-lysosome fusion in human macrophages. Scollard, D. M. and Gardner, I. D. ....(A)	596
fastidiously growing mycobacteria from armadillo livers infected with . . ., Isolation of. PORTAELS, F. and PATTYN, S. R. ....(C)	370
growth and death of . . . <i>in vivo</i> , Observations, calculations, and speculations on. Hastings, R. C. and Morales, M. J. ....(A)	579
—, of, in experimental animals and on artificial media. Pattyn, S. R. and Portaels, F. . .(A)	256
—, of, on M-Y 14b agar medium, Failure to validate. NAKAMURA, M., <i>et al.</i> ....(O)	480
—, of <i>Mycobacterium marinum</i> and . . . in mice, effect of body temperature and cell-mediated immunity on. Lancaster, R. D., <i>et al.</i> ....(A)	556
hapten modified, Improved leucocyte migration inhibition response of leucocytes from lepromatous leprosy patients with. Fotedar, A., <i>et al.</i> ....(A)	547
HLA-linked control of the course of . . . infections. de Vries, R. R. P. <i>et al.</i> ....(A)	260
IgA and IgM antibodies against . . . in cord sera and in patients with leprosy: An indicator of intrauterine infection in leprosy. Melsom, R., <i>et al.</i> ....(A)	397
immunoepidemiological studies on subclinical infection with. III. Geographic distribution of FLA-ABS test positive responders with special reference to their possible source of infection. Abe, M., <i>et al.</i> ....(A)	600
Immunoglobulin class specific antibodies in . . . in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy. Melsom, R., <i>et al.</i> ....(A)	397
—, G and M antibody responses to, in relation to various disease patterns; Humoral immunity in leprosy. Touw, J., <i>et al.</i> ....(A)	553
Immunotherapy with a mixture of . . . and BCG in different forms of leprosy and in Mitsuda-negative contacts. CONVIT, J., <i>et al.</i> ....(O)	415
<i>in vitro</i> effects of a suspension of . . . on the phagocytosis and lysis of candida by neutrophils (preliminary communication). Fliess, E. L., <i>et al.</i> ....(A)	394
—, enhancement of lymphoproliferative response to, by the inhibition of biosynthesis of prostaglandins. Izumi, S., <i>et al.</i> ....(A)	595
inoculation of, into the 'rhino mouse'. Kohsaka, K., <i>et al.</i> ....(A)	583
isoniazid, prothionamide and dapsone against . . . and some other mycobacteria, Activity of the combination of. Pattyn, S. R., <i>et al.</i> ....(A)	387
lipidic constituents of, isolated from experimentally infected armadillo. Asselineau, C., <i>et al.</i> ....(A)	131
lipids of <i>Mycobacterium gordonae</i> in comparison with those of . . . and of some other scotochromogenic mycobacteria. Studies on. Daffe, M., <i>et al.</i> ....(A)	400
lymphocyte transformation test (LTT) by phytohemagglutinin, lepromin and . . . in	

- lepromatous leprosy patients, negatives and positives: prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* . . . . .(A) 548
- monoclonal antibodies to . . . , production and initial characterization of; Immunochemical characterization of antigens of the leprosy bacillus. Miller, R. A., *et al.* . . .(A) 593
- , —, —, —, Production and partial characterization of. Gillis, R. P. and Buchanan, T. M. . . . . .(A) 547
- glycolipid-I antigen, Antibody responses of leprosy patients to. Umland, E. T., *et al.* . . . . .(A) 592
- isolated from the lymph of a lepromatous leprosy patient by means of the freeze-fracture technique, Studies on. Sanabria Negrin, J. G., *et al.* . . . . .(A) 556
- precursor coccoid organism, Inhibition of foot pad multiplication of, and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice. Bhide, M. B., *et al.* . . . . .(A) 400
- , —, —, —, Skin test response to, in a high leprosy endemic area as compared to lepromin. Chatterjee, B. R. . . . . .(A) 400
- whole organisms, comparison of, with other mycobacteria; Leprosy ELISA antigen coating buffers and antigens. Naka, S. O. and Douglas, J. T. . . . . .(A) 600
- Mycobacterium smegmatis* peroxidase; cross-reacting antigen with. Stavri, D., *et al.* . . .(A) 399
- Mycobacterial strains adapted to cultures separated from human lepromas. Identifying characteristics vis-a-vis . . . . Coudert, J., *et al.* . . . . .(A) 554
- nerve lesions of experimental animals inoculated with . . . , Comparative study of. Nishiura, M. and Fukunishi, Y. . . . . .(A) 589
- non-cultivable acid-fast bacilli in the environment and their relationship to, Occurrence of. Kaxda, J. . . . . .(A) 262
- novel phenolic glycolipid from . . . possibly involved in immunogenicity and pathogenicity. Hunter, S. W. and Brennan, P. J. . . . . .(A) 132
- pathomorphological changes in the internal organs of intact and . . . infected nine-banded armadillos. Vishnevetsky, F. E. and Juscenko, A. A. . . . . .(A) 257
- peribacillary substance of, Biochemical study of. Fukunishi, Y., *et al.* . . . . .(A) 589
- Propionibacterium acnes* treatment, Effects of, on the course of . . . infection in mice. Krahenbuhl, J. L., *et al.* . . . . . .(A) 558
- purified antigen of, and tuberculin PPD, *In vitro* lymphocyte stimulation using. Closs, O. and Reitan, L. J. . . . . . .(A) 259
- , armadillo-derived, in man, Testing of. (IMMLEP). . . . . .(N) 378
- , glycolipid from, Serological activity of. PAYNE, S. N., *et al.* . . . . .(C) 220
- , suspensions of, Preliminary studies of the metabolic activity of. Khanolkar, S. R. . . . . . .(A) 401
- rifampicins against, comparison of the bactericidal activity of a series of. Pattyn, S. R. . . . . . .(A) 538
- sciatic nerve compound action potential *in vitro* in normal and . . . infected mice, study of. Vidyasagar, P. B., *et al.* . . . . . .(A) 401
- skin scrape and skin biopsy methods in mouse foot pad experiments with, comparison of. Venkataramanaiah, H. N., *et al.* . . . . . .(A) 560
- specific antibodies to . . . by counter current electrophoresis, Demonstration of. Serology of leprosy. II. Jagannath, C. and Sengupta, D. N. . . . . .(A) 396
- superoxide dismutase, peroxidatic activity and catalase in . . . purified with armadillo liver. Wheeler, P. R. and Gregory, D. . . . . .(A) 557
- susceptibility of the armadillo to . . . infection, an index of; a preliminary report. Tissue response to lepromin. JOB, C. K., *et al.* . . . . . .(O) 177
- testing drug activity against, Statistical analysis of results obtained by two methods for. SHEPARD, C. C. . . . . . .(O) 96
- <sup>3</sup>H-thymidine in, Incorporation of, within differentiated human macrophages. Prasad, H. K. and Nath, I. . . . . . .(A) 132
- ultrastructural characteristics of *Mycobacterium bovis* BCG and . . . BINKHUYSEN, F. and DAS, P. K. . . . . . .(O) 76
- uptake of 3,4-dihydroxy[<sup>3</sup>H]phenylamine by . . . isolated from frozen (−80°C) armadillo tissue. Khanolkar, S. R., *et al.* . . . . . .(A) 555
- viability of, under normal and adverse atmospheric conditions. Kaur, S., *et al.* . . . . .(A) 555

<b><i>Mycobacterium lepraemurium</i>,</b>		
antibacterial resistance in mice infected with. Patel, P. J. ....(A)		133
antigen-specific reactions and resistance to . . . infection in mice, lack of correlation between. Curtis, J., <i>et al.</i> ....(A)		256
cycloheximide for cultivating <i>Mycobacterium leprae</i> and . . . in cell culture, Use of. Matsuo, Y. ....(A)		578
experimental infection with, in the CBA/J mice. Effects of preimmunization on the evolution of the disease. Corona, C. J. J., <i>et al.</i> ....(A)		402
—, leprosy with, in hairless mice ( <i>Mus musculus</i> ). Packchanian, E., <i>et al.</i> ....(A)		560
growth of, in cell-free liquid medium, Effect of pantoyl lactone on. Nakamura, M. ....(A)		556
—, —, stimulation of, in cell-free liquid medium by aspartic acid, sucrose, liposome, thymidine, and deoxyuridine (NDLASU medium). Nakamura, M. ....(A)		578
—, —, —, —, —, —, —, —, by DL aspartic acid. NAKAMURA, M. ....(O)		193
—, —, —, —, —, —, —, —, by vitamin K3 and B12. Nakamura, M. ....(A)		401
<i>in vitro</i> cultivation of, and its identification by animal inoculation. Ishaque, M. ....(A)		132
—, —, growth of, transition from <i>in vivo</i> grown to <i>in vitro</i> adaptation. Dhople, A. M. and Hanks, J. H. ....(A)		255
—, —, —, —, under the influence of macrophage cultures. Matsuo, Y. and Tatsukawa, H. ....(A)		401
macrophages and protective immunity in . . . infections in a 'resistant' (C57Bl) and a 'susceptible' (BALB/c) mouse strain. Preston, P. M. ....(A)		560
mice infected with, strain difference of immune responses in. Hirooka, Y., <i>et al.</i> ....(A)		558
murine leprosy in C3H mice vaccinated with extracts of . . . in admixture with <i>Mycobacterium bovis</i> (BCG). Lack of a sustained protection against. TURCOTTE, R. and LEMIEUX, S. ....(O)		494
<i>Mycobacterium bovis</i> BCG vaccination, Effect of, upon . . . infection. Lefford, M. J., <i>et al.</i> ....(A)		133
— antigens at the infection site, Repeated delayed-type hypersensitivity reaction against, do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. . .(A)		397
— grown in the Ogawa yolk medium. Study of growth factor for. II. Egg yolk protein fraction and effect of reducing reagents. Mori, T. and Nyein, M. ....(A)		559
oxydative phosphorylation in. Ishaque, M., <i>et al.</i> ....(A)		400
pathogenicity in mice and the ability of . . . to grow in tissue culture cells, relationship between. Nomaguchi, H., <i>et al.</i> ....(A)		578
Phagocytosis in leprosy. 5. Effect of the infection with . . . on the level of diverse hydrolic lysosomal enzymes of murine peritoneal macrophages. ROJAS-ESPINOSA, O., <i>et al.</i> ....(O)		306
<b><i>Mycobacterium marinum</i>,</b>		
body temperature and cell-mediated immunity, effect of, on the growth of . . . and <i>Mycobacterium leprae</i> in mice. Lancaster, R. D., <i>et al.</i> ....(A)		556
infection in the hind foot pad with, Response in distant lymph nodes of mice to. Mor, N., <i>et al.</i> ....(A)		559
—, with, Response in the hind foot pad and popliteal lymph node of C56Bl mice to. Mor, N., <i>et al.</i> ....(A)		559
intraperitoneal vaccination against challenge in the foot pad with, Protection of mice by. Ng, H., <i>et al.</i> ....(A)		560
intravenous infection with, Survival of BALB/c mice after. Ng, H., <i>et al.</i> ....(A)		560
<b><i>Mycobacterium phlei</i>,</b>		
lipid composition of, Effect of growth temperature and exogenous fatty acids on. Taneja, R., <i>et al.</i> ....(A)		567
<b><i>Mycobacterium scrofulaceum</i>,</b>		
mycobacteria of . . . type isolated from rat or mice lepromata are not aetiologic agents of murine leprosy. Ishaque, M. ....(A)		555
<b><i>Mycobacterium smegmatis</i>,</b>		
— peroxidase, cross-reacting antigen with <i>Mycobacterium leprae</i> . Stavri, D., <i>et al.</i> . . .(A)		399
<b><i>Mycobacterium tuberculosis</i>,</b>		
antigenic diversity of . . . and <i>Mycobacterium bovis</i> detected by means of monoclonal antibodies. Coates, A. R. M., <i>et al.</i> ....(A)		255

- H37Ra culture filtrate, Isolation and partial characterization of the most immunologically reactive antigen from. Reich, M., *et al.* .....(A) 567
- rifampicin and isoniazid in strains of, Resistance to. Siddiqi, S. H., *et al.* .....(A) 409
- Mycobacterium vaccae,**  
 biochemical correlation of . . . with *M. leprae*. Dutta, A. K., *et al.* .....(A) 554
- National Hansen's Disease Center,**  
 Audio-visual loan program at. ....(N) 516  
 International seminars on leprosy sponsored by American Leprosy Missions and. ....(N) 381
- Nepal,**  
 Green Pastures Leprosy Hospital, Ocular findings in leprosy: results of a survey in.  
 Brandt, F., *et al.* .....(A) 128  
 Malunga, Ocular findings in leprosy patients. A report of a survey in. Brandt, F. and  
 Malla, O. K. ....(A) 128  
 Nepal Leprosy Relief Association. Shrestha, K. B. ....(N) 123
- Nerve(s),**  
 — abscess in lepromatous leprosy. Malaviya, G. N., *et al.* .....(A) 543  
 — damage in leprosy; a teased fibre study of sciatic . . . in experimental mice. Bhat,  
 R. and Vaidya, M. C. ....(A) 557  
 —, —, —, —, Immunopathology of. MSHANA, R. N., *et al.* .....(C) 367  
 —, —, in tuberculoid leprosy. Reddy, P. K. and Prabhudass, N. ....(A) 545  
 — lesions of experimental animals inoculated with *M. leprae*. Comparative study of.  
 Nishiura, M. and Fukunishi, Y. ....(A) 589  
 sciatic . . . compound action potential *in vitro* in normal and *M. leprae* infected  
 mice, study of. Vidyasagar, P. B., *et al.* .....(A) 401  
 skin and peripheral, Discrepancy in the histopathological features of leprosy lesions  
 in. Report of a preliminary study. Srinivasan, J., *et al.* .....(A) 553  
 supraorbital, in leprosy, Compression neuritis of. Vaquero, N. L. and Soto, I. ....(A) 393
- Neuritis,**  
 compression . . . of the supraorbital nerve in leprosy. Vaquero, N. L. and Soto, I. ....(A) 393  
 in pregnancy and lactation. DUNCAN, M. E. and PEARSON, J. M. H. ....(O) 31  
 leprosy, Immunological implications of necrotic, cellular and vascular changes in:  
 light and electron microscopy. Dastur, D. K., *et al.* .....(A) 249  
 —, perineurotropic derivatives of acidic anti-inflammatory drugs for treatment of,  
 Fundamental studies on the possibility of. Tsutsumi, S. and Gidoh, M. ....(A) 590  
 —, Rehabilitation in leprosy. Abraham, J. C. ....(A) 266  
 —, ulnar . . . , Surgical management of. Kumar, K. ....(A) 406  
 ulnar . . . of leprosy, Role of surgical decompression in. Malaviya, G. N. and Ramu, G. ....(A) 565
- Neuropathy,**  
 autonomic functions in leprosy, study of. Dabholkar, V. R., *et al.* .....(A) 541  
 cardiovascular autonomic functions in leprosy. Sahasranam, K. V., *et al.* .....(A) 546  
 classification and treatment of, in Hansen's disease. Charosky, C. B. ....(A) 267  
 leprosy, Acceleration by isaxonine of muscle reinnervation; electrophysical demon-  
 stration in. Sebille, A., *et al.* .....(A) 565  
 neuropathic reactions in leprosy. Espana, A. ....(A) 389  
*Peripheral Neuropathies; Report of a WHO Study Group.* .....(B) 239
- Neutrophils,**  
*in vitro* effects of a suspension of *Mycobacterium leprae* on the phagocytosis and  
 lysis of candida by . . . (preliminary communication). Fliess, E. L., *et al.* .....(A) 394  
 motility of . . . and transformation of lymphocytes from normal individuals, *in vitro*  
 and *in vivo* effects of clofazimine on. Gatner, E. M. S., *et al.* .....(A) 386  
 — and lymphocyte functions in normal individuals and patients with lepromatous lep-  
 rosy, Effects of clofazimine alone or combined with dapsone on. Van Rensburg,  
 C. E., *et al.* .....(A) 539
- New Zealand,**  
 Pan Pacific Leprosy Symposium. Hargrave, J. C. ....(N) 232  
 The Leprosy Trust Board. ....(N) 237

<b>Nigeria,</b>		
Hepatitis-B virus infection in patients with leprosy: A serological study in a leprosar- ium in northern . . . . Fankule, Y. M. and Whittle, H. C. . . . .(A)		390
<b>Norway,</b>		
disappearance of leprosy from, Epidemiological aspects and implications of; some factors contributing to the decline. Irgens, L. M. . . . .(A)		261
<b>Nose,</b>		
in lepromatous leprosy; bacteriological and histopathological studies of patients treat- ed with dapsone monotherapy for varying periods of time. BARTON, R. P. E., <i>et al.</i> . .(O)		58
leprosy of. Rossi Vargas, J. . . . .(A)		392
<b>Nucleic acids,</b>		
fractionated, Skin tests with. Assessment of Dharmendra antigen. VI. Sinha, S., <i>et al.</i> . .(A)		553
<b>Nutrition,</b>		
delayed hypersensitivity after BCG in preschool children in relation to their nutrition- al status. Seth, V., <i>et al.</i> . . . . .(A)		268
influence of, on postvaccinal tuberculin sensitivity. Satyanarayana, K., <i>et al.</i> . . . . .(A)		135
<b>Obituaries (see also under surname),</b>		
Karat, Aaron Benedict Abiel. Brand, P. W. . . . .(Ob)		359
Lara, Casimiro B. Jose, F. A., Jr. . . . .(Ob)		213
Sagher, Felix. Sheskin, J. and Levy, L. . . . .(Ob)		508
<b>Ocular (see also Eye),</b>		
— disease in leprosy in Madagascar, Contribution to the study of. Andriantsoa-Ra- soavelonoro, V., <i>et al.</i> . . . . .(A)		127
— findings in leprosy: results of a survey in the Green Pastures Leprosy Hospital, Nepal. Brandt, F., <i>et al.</i> . . . . .(A)		128
—, —, in leprosy patients. Report of a survey in Malunga (Nepal). Brandt, F. and Malla, O. K. . . . .(A)		128
— lesions in lepromatous leprosy. Chovet, M., <i>et al.</i> . . . . .(A)		128
—, —, in leprosy. Reddy, S. C., <i>et al.</i> . . . . .(A)		247
<b>OMSLEP,</b>		
OMSLEP. Recording and Reporting System for Leprosy Patients. Lechat, M. F., <i>et al.</i> . . . . .(B)		524
<b>Onchocerciasis,</b>		
detection of circulating antigens in. Ouaiissi, A., <i>et al.</i> . . . . .(A)		267
paraclinical study of, in a leprosy and nonleprosy population (Mali). Penchenier, L., <i>et al.</i> . . . . .(A)		392
<b>Papua New Guinea,</b>		
Xylose absorption in Papua New Guineans with leprosy. Cook, G. C. . . . .(A)		541
<b>Paramedics,</b>		
employment sought for African paramedics. . . . .(N)		119
Teaching Guide for Paramedical Workers in Leprosy. Vol. 1. Chaudhary, D. S. . . . .(B)		383
<b>Pathogenesis,</b>		
novel phenolic glycolipid from <i>Mycobacterium leprae</i> possibly involved in immuno- genicity and pathogenicity. Hunter, S. W. and Brennan, P. J. . . . .(A)		132
of disease, role of regional body temperature in. Robard, D. . . . .(A)		131
— and classification of polar tuberculoid leprosy. Ridley, D. S. . . . .(A)		252
pathogenicity in mice and the ability of <i>M. lepraemurium</i> to grow in tissue culture cells, relationship between. Nomaguchi, H., <i>et al.</i> . . . . .(A)		578
<b>Pathology,</b>		
clinico-pathological study of so-called immune zones in leprosy. Sahni, U., <i>et al.</i> . . . .(A)		546
—, —, of testicular involvement in leprosy. Kumar, B., <i>et al.</i> . . . . .(A)		543
pathomorphology of leprosy, modern views of. Vishnevetsky, F. E. and Juscenko, A. A. . . . .(A)		254

- serum lysozyme (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., *et al.* .....(A) 246
- Peroxidase,**  
*Mycobacterium smegmatis* . . . , cross-reacting antigen with *Mycobacterium leprae*. Stavri, D., *et al.* .....(A) 399  
 superoxide dismutase, peroxidatic activity and catalase in *Mycobacterium leprae* purified with armadillo liver. Wheeler, P. F. and Gregory, D. ....(A) 557
- Phagocytosis,**  
 in leprosy. 5. Effect of the infection with *Mycobacterium lepraemurium* on the level of diverse hydrolic lysosomal enzymes of murine peritoneal macrophages. ROJAS-ESPINOSA, O., *et al.* .....(O) 306  
 — and lysis of candida by neutrophils, *in vitro* effects of a suspension of *Mycobacterium leprae* on, (preliminary communication). Fliess, E. L., *et al.* .....(A) 394
- Phenolic glycolipid(s),**  
 novel . . . from *Mycobacterium leprae* possibly involved in immunogenicity and pathogenicity. Hunter, S. W. and Brennan, P. J. ....(A) 132  
 structure and antigenicity of the specific . . . antigens and a related diacyl phthiocerol in secretions from *Mycobacterium leprae*. Hunter, S. W., *et al.* .....(A) 591
- Philippines, The,**  
 Philippine Journal of Dermatology and Leprosy. Reyes-Javier, P. D. ....(N) 233  
 Third Standardization Workshop for Joint Chemotherapy Trials (Leonard Wood Memorial Laboratory/Cebu/Philippines). Reich, C. V. ....(N) 124
- Phospholipid(s),**  
 — deacylating activities in murine leprosy bacilli. Kashiwabara, Y. and Nakagawa, H. ..(A) 588
- Phytohemagglutinin,**  
 lymphocyte transformation test (LTT) by . . . , lepromin and *M. leprae* in lepromatous leprosy patients, negatives and positives: prognostic value compared with that of lepromin. Guimaraes Pagnano, P. M., *et al.* .....(A) 548  
 — (PHA)-induced lymphocyte transformation, *In vitro* effect of DDS on. Ghei, S. K., *et al.* .....(A) 395
- Pregnancy,**  
 and leprosy: the consequence of alterations of cell-mediated and humoral immunity during . . . and lactation. DUNCAN, M. E., *et al.* .....(O) 425  
 Clofazimine in . . . complicated by leprosy. Farb, H., *et al.* .....(A) 243  
 neuritis in . . . and lactation. DUNCAN, M. E. and PEARSON, J. M. H. ....(O) 31
- Properdin,**  
 genetic polymorphisms of . . . factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and health controls from Thailand. Greiner, J., *et al.* .....(A) 130
- Prostaglandin(s),**  
 inhibition of biosynthesis of, *In vitro* enhancement of lymphoproliferative response to *M. leprae* by. Izumi, S., *et al.* .....(A) 595  
 — dependent regulation of the *in vitro* proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal donors and from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* .....(A) 129
- Prosthetics,**  
 peg prosthesis in leprosy, Observations on. Kulkarni, V. N. and Mehta, J. M. ....(A) 564
- Protein(s),**  
 egg yolk . . . fraction and effect of reducing reagents. Study of growth factor for *Mycobacterium lepraemurium* grown in the Ogawa yolk medium. II. Mori, T. and Nyein, M. ....(A) 559  
 electrophoretic pattern of, in lepromatous leprosy. Baji, P. S., *et al.* .....(A) 540  
 — deficiency, Disposition of dapsone in; an experimental study in mice. Venkatesan, K., *et al.* .....(A) 540

serum . . . bound fucose (PBF) in untreated leprosy patients. Venkatesan, K., <i>et al.</i> . . .(A)	393
total and differential serum . . . and globulins in leprosy. Kumar, B., <i>et al.</i> . . . . .(A)	543
tuberculin purified . . . derivative and non-mycobacterial stimulants, effect of dapsone treatment on the response to <i>Mycobacterium leprae</i> antigens. <i>In vitro</i> lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., <i>et al.</i> . . . . .(O)	455
<b>Prothionamide,</b>	
isoniazid, . . . and dapsone against <i>Mycobacterium leprae</i> and some other mycobacteria, Activity of. Pattyn, S. R., <i>et al.</i> . . . . .(A)	387
low dosage, role of, with and without 4,4'-diaminodiphenyl sulphone for use with isoniazid in the treatment of experimental mouse tuberculosis. Grosset, J., <i>et al.</i> . . .(A)	407
<b>Purified protein derivative (PPD),</b>	
<i>in vitro</i> lymphocyte stimulation using a purified antigen of <i>M. leprae</i> and tuberculin . . . . Closs, O. and Reitan, L. J. . . . . .(A)	259
tuberculin . . . and non-mycobacterial stimulants; effect of dapsone treatment on the response to <i>Mycobacterium leprae</i> antigens. <i>In vitro</i> lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., <i>et al.</i> . . .(O)	455
<b>Radioimmunoassay,</b>	
and other serological tests and their application in epidemiological work. Harboe, M. . . . . .(A)	261
of tuberculous antigen. Kadival, G. V., <i>et al.</i> . . . . .(A)	567
<b>Rat(s),</b>	
glycolytic processes in . . . infected with <i>M. leprae</i> , influence of antileprosy drugs on. Rezaev, A. A. . . . . .(A)	245
mycobacteria of <i>Mycobacterium scrofulaceum</i> type isolated from . . . or mice lepromata are not the aetiologic agents of murine leprosy. Ishaque, M. . . . . .(A)	555
nude . . . as an experimental lepromatous leprosy model (continued): effects of carrageenans, splenectomy, and treatment with thymus cells. Nakamura, K. and Yogi, Y. . . . . .(A)	587
<b>Reaction(s),</b>	
antigen-specific, lack of correlation between . . . and resistance to <i>Mycobacterium lepraemurium</i> infection in mice. Curtis, J., <i>et al.</i> . . . . . .(A)	256
borderline-tuberculoid leprosy in . . . presenting as photodermatitis; a case report. Fekete, E., <i>et al.</i> . . . . . .(A)	390
early (Fernandez) and late (Mitsuda) . . . , Correlation between, in children and adolescent non-contacts and without manifestations of leprosy, tested with different concentrations of armadillo antigen in three double-blind trials. Bechelli, L. M., <i>et al.</i> . . . . . .(A)	547
egg-yolk, produced by human and murine leprosy lesions and its cultural significance on primary isolation. Koseki, Y., <i>et al.</i> . . . . . .(A)	577
etiopathogenesis of reactional episodes. Pacin, A. and Fliess, E. L. . . . . .(A)	398
hansenic, Dimorphous hanseniasis with outbreaks of, and visceral lesions. . . . . .(A)	246
hypersensitivity, Pharmacologically active mediators of, in the blood of lepromatous patients with erythema nodosum leprosum. Saha, K. and Lahiri, S. C. . . . . .(A)	252
interdermal . . . following integral lepromin and lepromin treated with ultrasound in normal individuals, study comparing. Karazawa, E. H., <i>et al.</i> . . . . . .(A)	550
lepra, Osteo-articular changes in. Charosky, C. B. . . . . . .(A)	388
—, progressive. Guha, P. K. and Ghosh, M. . . . . . .(A)	542
—, thalidomide treatment of, Iron content of skin before and after. Sheskin, J., <i>et al.</i> . . . . . .(A)	247
—, visceral manifestations of. Ortiz, M. C. . . . . . .(A)	391
Mitsuda, comparative study with whole human and armadillo lepromin in 50 leprosy patients. Zambrano, M. T., <i>et al.</i> . . . . . .(A)	129
necrotizing lepra, spectrum of. (Allergic cutaneous vasculitis; Lucio phenomenon.) A proposed intermediate lepra reaction. Peyri, L., <i>et al.</i> . . . . . .(A)	545
neuropathic, in leprosy. Espana, A. . . . . . .(A)	389
repeated delayed-type hypersensitivity, against <i>Mycobacterium lepraemurium</i> anti-	

- gens at the infection site do not affect bacillary multiplication in C3H mice. Løvik, M. and Closs, O. . . . .(A) 397
- Type 1 lepra, induced by lepromin test; a case report. Dong Li-Wen, *et al.* . . . . .(A) 541
- type 1 . . . , short-term, multi-drug chemotherapy of leprosy and. PFALTZGRAFF, R. E. . .(C) 365
- Rees, Dr. R. J. W.,**  
to retire from National Institute for Medical Research. . . . .(N) 381
- Rehabilitation,**  
All Africa Leprosy and Rehabilitation Training Centre (ALERT) international courses program; 1982 (Ethiopia) . . . . .(N) 226
- ILO/DANIDA Asian regional seminar on vocational rehabilitation; Bombay (India). . .(N) 227
- in leprosy; leprosy neuritis. Abraham, J. C. . . . .(A) 266
- , —, socio-anthropological aspects. Pina, N. C. and Manzi, R. O. . . . .(A) 564
- metatarsal head pressure (MHP) sores in leprosy patients. Pati, L. and Behera, F. . . .(A) 406
- Renal** (*see also* Kidney(s)),  
— amyloidosis complication of tuberculoid leprosy and plasma cell dyscrasia; case reports of three patients. Seggie, J. and Gelfand, M. . . . .(A) 546
- changes in leprosy, Study of. PHADNIS, M. C., *et al.* . . . . .(O) 143
- transplantation in leprosy. DATE, A., *et al.* . . . . .(O) 56
- Respiratory tract,**  
*Leprosy of the Upper Respiratory Tract. Atlas of Clinical Picture and Notes on the Research (1938–1943).* Yoshie, Y. . . . .(B) 384
- Rheumatoid arthritis,**  
detection of anti-collagen type I and II antibodies by an immunoenzymatic technique (ELISA): results in . . . , systemic lupus erythematosus and leprosy. Meghlaoui, A. . .(A) 250
- does . . . have a clinicopathological spectrum similar to that of leprosy. Panayi, G. S. . . . .(A) 392
- Ridley-Jopling scale,**  
in clinical practice, Applicability of . . . Verma, K. C., *et al.* . . . . .(A) 393
- Rifampin,**  
bactericidal activity of a series of . . . against *Mycobacterium leprae*, comparison of. Pattyn, S. R. . . . .(A) 538
- immunodepressive effect of . . . (RFP) on cell-mediated immunity of guinea pigs examined by rabbit red blood cell rosette formation method. Gidoh, M. and Tsutsumi, S. . . . .(A) 386
- resistance to . . . and isoniazid in strains of *Mycobacterium tuberculosis*. Siddiqi, S. H., *et al.* . . . . .(A) 409
- , once-monthly, plus daily dapsone in initial treatment of lepromatous leprosy. Yawalkar, S. J., *et al.* . . . . .(A) 540
- treatment of paucibacillary leprosy, Follow-up on short-course two months'. Warndorff, J., *et al.* . . . . .(A) 245
- therapeutic effect of oximes of 3-formylrifamycin SV in the treatment of leprosy. Ji Baohung, *et al.* . . . . .(A) 537
- three drugs used most frequently for leprosy are dapsone, . . . and clofazimine. . . .(N) 235
- Sarcoidosis,**  
tuberculoid leprosy or . . . ; a diagnostic dilemma. Ramanujam, K. . . . .(A) 545
- Sagher, Felix,**  
obituary, Sheskin, J. and Levy, L. . . . .(Ob) 508
- Sera, of leprosy patients,**  
adenosine deaminase activity in, study of. Chon, J. Y., *et al.* . . . . .(A) 394
- anomalous isoenzymes of lactate dehydrogenase in. Saoji, A. M. and Kelkar, S. S. . .(A) 557
- antibodies to sulfolipids in. KHULLER, G. K., *et al.* . . . . .(O) 319
- beta hydroxy beta methyl glutaryl CoA reductase in . . . , Indirect assay of; a further probe into cholesterol metabolism. Kannan, K. B., *et al.* . . . . .(A) 542
- cord sera, IgA and IgM antibodies against *Mycobacterium leprae* in . . . and in patients with leprosy; indicator of intrauterine infection in leprosy. Melsom, R., *et al.* . .(A) 397

determination of three main antileprosy drugs and their main metabolites in serum by high performance liquid chromatography. Gidoh, M., <i>et al.</i> . . . . .(A)	244
lactic dehydrogenase isoenzymes in. Garcia, R., <i>et al.</i> . . . . .(A)	542
normal bacillary lepromin incubated with sera from patients with distinct clinical forms of leprosy, Cutaneous response to. Corona, C. J. J., <i>et al.</i> . . . . .(A)	249
—, enzyme profile in tuberculoid leprosy. Bulakh, P. M., <i>et al.</i> . . . . .(A)	541
—, lactate dehydrogenase isoenzyme patterns in leprosy, Qualitative studies of. Saoji, A. M. and Kelkar, S. S. . . . . .(A)	247
—, lysozyme (muramidase) levels in the normal and various pathological states in Kenyan Africans. Kasili, E. G., <i>et al.</i> . . . . .(A)	246
—, immunoglobulins and autoantibodies during and after erythema nodosum leprosum (ENL). SHARMA, V. K., <i>et al.</i> . . . . .(O)	159
—, inhibitory factor in lepromatous leprosy; its effect on the pre-S-phase cell cycle kinetics of mitogen-stimulated normal human lymphocytes. Potts, R. C., <i>et al.</i> . . . .(A)	251
—, protein bound fucose (PBF) in untreated leprosy patients. Venkatesan, K., <i>et al.</i> . . . . .(A)	393
—, proteins and globulins in leprosy, Total and differential. Kumar, B., <i>et al.</i> . . . . .(A)	543
—, trace elements and vitamin A in leprosy subtypes. Sher, R., <i>et al.</i> . . . . .(A)	128
<b>Skin,</b>	
free . . . flap, Surgical treatment of plantar ulcer with, in leprosy patients: a case report. Dong Li-Wen, <i>et al.</i> . . . . .(A)	267
histopathological features of leprosy lesions in the . . . and peripheral nerve, Discrepancy in. Report of a preliminary study. Srinivasan, J., <i>et al.</i> . . . . .(A)	553
human leprosy . . . lesions, Immunohistopathologic study of $\beta$ -glucuronidase and lysozyme in. Matsuo, E., <i>et al.</i> . . . . .(A)	599
ichthyotic and nonichthyotic . . . and plasma of leprosy patients with and without clofazimine therapy, Vitamin A levels of. Bharadwaj, V. P., <i>et al.</i> . . . . .(A)	535
Iron content of . . . before and after thalidomide treatment of lepra reaction. Sheskin, J., <i>et al.</i> . . . . .(A)	247
malignant . . . tumors, Leprosy and. Cardama, J. E., <i>et al.</i> . . . . .(A)	388
— lesions across the spectrum of leprosy, immunoperoxidase study of immunological factors in. RIDLEY, M. J., <i>et al.</i> . . . . .(O)	11
— of leprosy patients, apparently normal, Histologic profile in. Sakuntala, R., <i>et al.</i> . .(A)	552
— scrape and . . . biopsy methods, comparison of, in mouse foot pad experiments with <i>M. leprae</i> . Venkataramanaiah, H. N., <i>et al.</i> . . . . .(A)	560
— smears of leprosy patients, study on selection of sites for acid-fast bacilli in. Kim, Y. . . . .(A)	391
specific . . . delayed hypersensitivity (DH) inducing antigens from lepromin, Attempts for purification of. Assessment of Dharmendra antigen. V. Sengupta, U., <i>et al.</i> . . . . .(A)	552
<b>Skin test(s),</b>	
— reagent LRA6, a cell-free extract from armadillo-derived <i>Mycobacterium leprae</i> , epidemiological evaluation, in Burma, of. Part I. Leprosy patients. SHIELD, M. J., <i>et al.</i> . . . . .(O)	436
— Part 2. Close contacts and non-contacts of bacilliferous leprosy patients. SHIELD, M. J. and STANFORD, J. L. . . . . .(O)	446
— reagents, control of specificity of. Magnusson, M. . . . .(A)	263
— response, Specific, in children of patients with indeterminate leprosy, tuberculoid leprosy, and lepromatous leprosy. Gimenez, M. and Morini, J. C. . . . . .(A)	395
—, —, to <i>M. leprae</i> precursor coccoid organisms in a high leprosy endemic area as compared to lepromin. Chatterjee, B. R. . . . . .(A)	400
with fractionated nucleic acids. Assessment of Dharmendra antigen. VI. Sinha, S., <i>et al.</i> . . . . .(A)	553
<b>South Africa,</b>	
pattern of age-specific tuberculin hypersensitivity in two groups of South African schoolchildren. Gatner, E. M. S. and Rubinstein, E. . . . . .(A)	134
<b>Spain,</b>	
International courses on leprosy at Fontilles. . . . . .(N)	378

**Spleen,**

- effects of carrageenans, splenectomy, and treatment with thymus cells; the nude rat as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. . . . .(A) 587
- inhibition of foot pad multiplication of *M. leprae* precursor coccoid organism and passive transfer of DTH response to normal mice through infusion of splenic cells of such vaccinated mice. Bhide, M. B., *et al.* . . . . .(A) 400
- role of the . . . in the formation of the lepromatoid lesions; the hereditarily athymic asplenic (LASAT) mouse as an experimental lepromatous leprosy model (continued). Nakamura, K. and Yogi, Y. . . . .(A) 586

**Stain(s),**

- blood staining of the cornea in Hansen's disease; a light- and electron-microscopic study. Yoshimura, M., *et al.* . . . . .(A) 248
- fluorescent staining procedure for determining the viability of mycobacterial cells. KVACH, J. and VERAS, J. R. . . . .(O) 183
- oxidative acid-fast staining for non-deparaffinized sections of leprosy tissue, modified procedure of. Yong, Z. *et al.* . . . . .(A) 131

**Sulfone(s),**

- current status of. Consigli, C. A. . . . .(A) 385
- Plasma-mediated sulfonamide resistance in *Haemophilus ducreyi*. Albritton, W. L., *et al.* . . . . .(A) 406
- resistant leprosy, clinical and experimental studies on. Li Wenzhong, *et al.* . . . . .(A) 126

**Superoxide,**

- dismutase, peroxidatic activity and catalase in *Mycobacterium leprae* purified with armadillo liver. Wheeler, P. F. and Gregory, D. . . . .(A) 557

**Surgery,**

- acute onset in leprosy patients, Surgical problems of, and their management in leprosy control programmes. Prasad, S. B. . . . .(A) 565
- Leprosy (transactions of the Seventh International Congress of Plastic and Reconstructive Surgery). Duerksen, F. . . . .(A) 405
- leprous ulnar neuritis, Surgical management of. Kumar, K. . . . .(A) 406
- plantar ulcer, surgical treatment of, with free skin flap in leprosy patients: case report. Dong Li-Wen, *et al.* . . . . .(A) 267
- sublimus tendons, Effects on fingers of leprosy patients having surgical removal of. Reddy, N. R. and Kolumban, S. L. . . . .(A) 406
- ulnar neuritis of leprosy, Role of surgical decompression in. Malaviya, G. N. and Ramu, G. . . . .(A) 565

**Switzerland,**

- Emmaus, 25th anniversary of. . . . .(N) 236
- IMMLEP Steering Committee meetings. . . . .(N) 516
- testing of purified armadillo-derived *Mycobacterium leprae* in man; IMMLEP . . . . .(N) 378
- THELEP reviews progress of field trials. . . . .(N) 379
- THELEP seeks trial sites. . . . .(N) 379

**Syphilis,**

- in Hansen's disease patients at Plaza Municipality (Cuba) during 1977. Serology to determine. Cardenas, Z. L., *et al.* . . . . .(A) 541
- in patients with Hansen's disease. MURRAY, K. A. . . . .(O) 152

**Tanzania,**

- leprosy and the possible role of village 10-cell leaders in control in Muheza District, prevalence survey on. Van Praag, E. and Mwankemwa, S. A. . . . .(A) 266

**Taste,**

- disturbance of, in leprosy. Soni, N. K. and Chatterji, P. . . . .(A) 248
- loss of . . . and somatic sensations over the tongue in leprous facial palsy; a case report. Malaviya, G. N. and Ramu, G. . . . .(A) 391

**Temperature,**

- body . . . and cell-mediated immunity, Effect of, on the growth of *Mycobacterium marinum* and *Mycobacterium leprae* in mice. Lancaster, R. D., *et al.* . . . . .(A) 556

—, —, regional, role of, in the pathogenesis of disease. Robard, D. . . . .(A)	131
growth . . . and exogenous fatty acids, Effect of, on the lipid composition of <i>Mycobacterium phlei</i> . Taneja, R., <i>et al.</i> . . . . .(A)	567
<b>Testes,</b>	
immunoreactivity <i>in vitro</i> to human . . . in patients with lepromatous leprosy. Wall, J. R. and Walters, B. A. J. . . . .(A)	255
testicular involvement in leprosy, Clinico-pathological study of. Kumar, B., <i>et al.</i> . . . .(A)	543
<b>Tetanus,</b>	
natural resistance against, in patients with lepromatous leprosy. Saha, K., <i>et al.</i> . . . .(A)	392
<b>Thailand,</b>	
clinical and epidemiological features of leprosy in two resettlement villages. Vithayasai, V., <i>et al.</i> . . . . .(A)	601
genetic polymorphisms of properdin factor B(Bf), the second component (C2) and the fourth component (C4) of complement in leprosy patients and healthy controls from . . . . Greiner, J., <i>et al.</i> . . . . .(A)	130
<b>Thalidomide,</b>	
does not affect polymorphonuclear leukocyte (PMN) chemotaxis. Miyachi, Y. and Ozaki, M. . . . .(A)	387
— treatment of lepra reaction, Iron content of skin before and after. Sheskin, J., <i>et al.</i> . . . . .(A)	247
<b>The Leprosy Mission (TLM),</b>	
Lady Richardson named chairman of. . . . .(N)	233
Miss Grace Bennett retires from, in Korea. . . . .(N)	376
— International teaching and learning in leprosy report for 1981. . . . .(N)	382
<b>THELEP,</b>	
Annual report of IMMLEP and THELEP 1980–1981. . . . .(N)	233
reviews progress of field trials. . . . .(N)	379
seeks trial sites. . . . .(N)	379
Tenth meeting of THELEP Steering Committee held in Rangoon. . . . .(N)	225
<b>Therapy,</b>	
clofazimine, Vitamin A levels of ichthyotic and nonichthyotic skin and plasma of leprosy patients with and without. Bharadwaj, V. P., <i>et al.</i> . . . . .(A)	535
for leprosy, Intramuscular injection of dapsone in: a new approach. Modderman, E. S. M., <i>et al.</i> . . . . .(A)	387
Therapeutic effect of oximes of 3-formylrifamycin SV in the treatment of leprosy. Ji Baohung, <i>et al.</i> . . . . .(A)	537
tuberculosis, Immune responses and immunostimulation in. Gatner, E. M. S. and Anderson, R. . . . .(A)	566
<b>Thiacetazone (TBI),</b>	
severe dermatitis induced by the use of, in the treatment of tuberculosis in the state of Rio Grande do Sul (Brazil). . . . .(A)	243
<b>Thiazole(s),</b>	
thiocarbanilides derived from 2-(4'-aminophenyl) . . . and 4-(4'-aminophenyl) . . . for <i>in vitro</i> antituberculosis activity, Synthesis and study of. Nerurkar, C. B., <i>et al.</i> . . .(A)	387
2-aryloxy thioisonicotinamides analogous to ethionamide and . . . derived therefrom as antituberculosis agents, Synthesis and study of. Pandalwar, S. L., <i>et al.</i> . . . . .(A)	387
<b>Thymidine,</b>	
cell-free liquid medium by aspartic acid, sucrose, liposome, . . . , and deoxyuridine (NDLASU medium), Stimulation of growth of <i>Mycobacterium lepraemurium</i> in. Nakamura, M. . . . .(A)	578
<sup>3</sup> H-thymidine in <i>Mycobacterium leprae</i> within differentiated human macrophages, Incorporation of. Prasad, H. K. and Nath, I. . . . .(A)	132

- Thymosin,**  
pig's, combined with dapsone, Pilot-trial of treatment of leprosy by. . . . .(A) 551
- Thymus,**  
— dependent lymphocytes in leprosy. I. T lymphocyte subpopulations defined by monoclonal antibodies. MSHANA, R. N., *et al.* . . . . .(O) 291  
treatment with . . . cells, nude rat as an experimental lepromatous leprosy model (continued): the effects of carrageenans, splenectomy, and. Nakamura, K. and Yogi, Y. . . . .(A) 587
- Tissue(s),**  
frozen (–80°C) armadillo, Uptake of 3,4-dihydroxy[<sup>3</sup>H]phenylalamine by *Mycobacterium leprae* isolated from. Khanolkar, S. R., *et al.* . . . . .(A) 555  
leprosy, Demonstration of mycobacterial antigens in. MSHANA, R. N., *et al.* . . . . .(O) 1  
non-deparaffinized sections of leprosy . . . , modified procedure of oxidative acid-fast staining for. Zhou Yong, *et al.* . . . . .(A) 131  
T cell subsets in the peripheral blood and . . . of patients with leprosy. Modlin, R. L., *et al.* . . . . .(A) 596  
— culture cells, relationship between pathogenicity in mice and the ability of *M. leprae* to grow in. Nomaguchi, H., *et al.* . . . . .(A) 578  
— response to lepromin; an index of susceptibility of the armadillo to *M. leprae* infection; a preliminary report. JOB, C. K., *et al.* . . . . .(O) 177
- Tongue,**  
loss of taste and somatic sensations over the . . . in leprosy facial palsy; a case report. Malaviya, G. N. and Ramu, G. . . . .(A) 391
- Toxicity,**  
of clofazimine, Study of, with special reference to structural and functional status of small intestine. Kumar, B., *et al.* . . . . .(A) 537
- Transfusions,**  
of fresh blood, donated by healthy but lepromin positive patients, Reversion of the downhill course of active lepromatous leprosy by repeated. Saha, K., *et al.* . . . . .(A) 552
- Trials,**  
double blind . . . on the effect of certain soluble cytoplasmic mycobacterial antigens on the late reactivity to lepromin. HADDAD, N., *et al.* . . . . .(O) 325  
pilot-. . . of treatment of leprosy by pig's thymosin combined with dapsone. . . . .(A) 551  
short-term clinical . . . monitored by mouse foot pad inoculation, brief review of experiences with. Shepard, C. C. . . . .(A) 245  
THELEP reviews progress of field . . . . .(N) 379  
THELEP seeks . . . sites. . . . .(N) 379  
Third Standardization Workshop for Joint Chemotherapy Trials (Leonard Wood Memorial Laboratory/Cebu/Philippines). Reich, C. V. . . . .(N) 124  
three double-blind . . . , Correlation between early (Fernandez) and late (Mitsuda) reactions in children and adolescent non-contacts and without manifestations of leprosy; tested with different concentrations of armadillo antigen in. Bechelli, L. M., *et al.* . . . . .(A) 547
- Tuberculin,**  
age-specific . . . hypersensitivity in two groups of South African schoolchildren, pattern of. Gatner, E. M. S. and Rubinstein, E. . . . .(A) 134  
postvaccinal . . . sensitivity, Influence of nutrition on. Satyanarayana, K., *et al.* . . . .(A) 135  
— PPD, *In vitro* lymphocyte stimulation using a purified antigen of *M. leprae* and. Closs, O. and Reitan, L. J. . . . .(A) 259  
— purified protein derivative, effect of dapsone treatment on the response to *Mycobacterium leprae* antigens, . . . and non-mycobacterial stimulants. *In vitro* lymphocyte stimulation in patients with lepromatous and borderline tuberculoid leprosy. REITAN, L. J., *et al.* . . . . .(O) 455

**Tuberculosis,**

- chemotherapy in pulmonary . . . , Shortest possible acceptable effective ambulatory.  
Mehrotra, M. L., *et al.* . . . . .(A) 408
- experimental mouse, electron microscopy study of intra-cellular mycobacteria in.  
Kanai, K., *et al.* . . . . .(A) 135
- , —, role of low dosage prothionamide with and without 4,4'-diaminodiphenyl sul-  
phone for use with isoniazid in the treatment of. Grosset, J., *et al.* . . . . .(A) 407
- immune complexes in the spectrum of. Brostoff, J., *et al.* . . . . .(A) 134
- , responses and immunostimulation in . . . therapy. Gatner, E. M. S. and Ander-  
son, R. . . . .(A) 566
- patients with pulmonary . . . , Circulating immunoglobulin levels in, with special ref-  
erence to IgE. Gatner, E. M. S., *et al.* . . . . .(A) 566
- , with . . . or leprosy, Absence of antibodies to muramyl dipeptide in. Bahr, G.  
M., *et al.* . . . . .(A) 394
- , —, —, —, Prostaglandin-dependent regulation of the *in vitro* proliferative re-  
sponse to mycobacterial antigens of peripheral blood lymphocytes from normal  
donors and from. Bahr, G. M., *et al.* . . . . .(A) 129
- pulmonary . . . patients, Immune status in. Mirza, A. . . . .(A) 567
- thiacetazone in the treatment of, in the state of Rio Grande do Sul (Brazil), Severe  
dermatitis induced by the use of. . . . .(A) 243
- control: world review. . . . .(A) 568

**Tumors,**

- malignant skin, Leprosy and. Cardama, J. E., *et al.* . . . . .(A) 388

**Ultrasound,**

- Hypodermis sclerodermiformis; successful treatment with. Rowe, L. and Cantwell,  
A., Jr. . . . .(A) 408
- interdermal reactions following integral lepromin and lepromin treated with . . . in  
normal individuals, study comparing the. Karazawa, E. H., *et al.* . . . . .(A) 550

**Ultrastructural characteristics,**

- features of the multiplication of human and murine leprosy bacilli in macrophages of  
nude mice. FUKUNISHI, Y., *et al.* . . . . .(O) 68
- of cells in lesions of lepromatous and tuberculoid leprosy. Liu Zijun, *et al.* . . . . .(A) 551
- of histoid leproma, Observations on. LIU JIHE, *et al.* . . . . .(O) 471
- of *Mycobacterium bovis* BCG and *Mycobacterium leprae*. BINKHUYSEN, F. and  
DAS, P. K. . . . .(O) 76
- of the dermal microvasculature in leprosy. TURKEL, S. B., *et al.* . . . . .(O) 164

**United Kingdom,**

- International Seminar on the Prevention of Disablement. Browne, S. G. . . . .(N) 121
- Lady Richardson named chairman of The Leprosy Mission. . . . .(N) 233
- National Institute for Medical Research, Dr. R. J. W. Rees to retire from. . . . .(N) 381
- The Leprosy Mission (TLM) International teaching and learning in leprosy report for  
1981. . . . .(N) 382

**U.S.A.,**

- American Association for the Advancement of Science, Prime Minister Gandhi (In-  
dia) addresses the. . . . .(N) 522
- Audio-visual loan program at National Hansen's Disease Center. . . . .(N) 516
- closing of Public Health Service hospitals. . . . .(N) 234
- Emmanuel Faria named to ALM Board. . . . .(N) 521
- epidemiologic evaluation of leprosy in New York City. . . . .(A) 562
- Heiser Program for Research in Leprosy; 1983 opportunities. . . . .(N) 380
- , —, the first five years. . . . .(N) 379
- International seminars on leprosy sponsored by American Leprosy Missions and Na-  
tional Hansen's Disease Center. . . . .(N) 381
- Leonard Wood Memorial Scientific Symposium, Bellagio, Italy, 2-4 June 1982. . . . .(N) 521

Leprosy Scientific Memoranda to resume in fall 1982 by Leonard Wood Memorial. . . .(N)	522
1982 International Health Conference scheduled. . . . .(N)	122
27th International Seminar on Leprosy, details announced. . . . .(N)	234
233 new leprosy cases in. . . . .(A)	258
unwanted import on the rise: leprosy. . . . .(A)	563
<b>U.S.—Japan Cooperative Medical Science Program,</b>	
Seventeenth Joint Leprosy Conference, Sendai, Japan, 25–27 July 1982. . . . .(—)	569
<b>Upper Volta,</b>	
four cases of dapsone resistant leprosy in. Pattyn, S. R., <i>et al.</i> . . . . .(A)	244
<b>U.S.S.R.,</b>	
incidence of leprosy in family members of patients (according to the materials of the Astrakhan Zone). Kogan, V. R., <i>et al.</i> . . . . .(A)	262
<b>Vaccination,</b>	
BCG . . . in leprosy. PRICE, J. E. . . . .(E)	205
BCG . . . of children against leprosy in Uganda: final results. Stanley, S. J., <i>et al.</i> . . . .(A)	265
intraperitoneal . . . against challenge in the foot pad with <i>Mycobacterium marinum</i> , Protection of. Ng, H., <i>et al.</i> . . . . .(A)	560
<i>Mycobacterium bovis</i> BCG . . . , Effect of, upon <i>Mycobacterium lepraemurium</i> infection. Lefford, M. J., <i>et al.</i> . . . . .(A)	133
with extracts of <i>Mycobacterium lepraemurium</i> in admixture with <i>Mycobacterium bovis</i> (BCG), Lack of a sustained protection against murine leprosy in C3H mice vaccinated. TURCOTTE, R. and LEMIEUX, S. . . . .(O)	494
<b>Vaccine,</b>	
BCG . . . induced lupus vulgaris. Izumi, A. K. and Matsunaga, J. . . . .(A)	407
leprosy . . . (Letter to Editor). Brennan, P. J. . . . .(A)	534
potential antileprosy . . . from killed ICRC bacilli; a clinicopathological study. Deo, M. G., <i>et al.</i> . . . . .(A)	130
<b>Vasculitis,</b>	
allergic cutaneous . . . ; (Lucio phenomenon). spectrum of the necrotizing lepra reactions. A proposed intermediate lepra reaction. Peyri, L., <i>et al.</i> . . . . .(A)	545
leukocytoclastic . . . . Mackel, S. E. and Jordan, R. E. . . . .(A)	407
<b>Visceral leprosy,</b>	
dimorphous hanseniasis with outbreaks of hansenic reaction and visceral lesions. . . . .(A)	246
visceral manifestations of lepra reactions. Ortiz, M. C. . . . .(A)	391
<b>Vitamin A,</b>	
in leprosy subtypes, Serum trace elements and. Sher, R., <i>et al.</i> . . . . .(A)	128
— levels of ichthyotic and nonichthyotic skin and plasma of leprosy patients with and without clofazimine therapy. Bharadwaj, V. P., <i>et al.</i> . . . . .(A)	535
<b>Vitamin B12,</b>	
growth stimulation of <i>Mycobacterium lepraemurium</i> in cell-free liquid medium by vitamin K3 and. Nakamura, M. . . . .(A)	401
<b>Vitamin K3,</b>	
growth stimulation of <i>Mycobacterium lepraemurium</i> in cell-free liquid medium by . . . and B12. Nakamura, M. . . . .(A)	401
<b>World Health Organization (WHO),</b>	
chemotherapy of leprosy for control programmes. . . . .(A)	536
Kuala Lumpur meeting on social and economic aspects of leprosy (UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases). . . .(N)	376
Report of a WHO study group. <i>Peripheral Neuropathies</i> . . . . .(B)	239
testing of purified armadillo-derived <i>Mycobacterium leprae</i> in man; IMMLEP . . . . .(N)	378
THELEP reviews progress of field trials . . . . .(N)	379
THELEP seeks trial sites. . . . .(N)	379

— and Council for International Organizations of Medical Sciences. <i>Proposed International Guidelines for Biomedical Research Involving Human Subjects</i> . . . . .(B)	383
— workshop, Bombay. <i>Urban Leprosy Control</i> . . . . .(B)	383
<b>Xylose,</b>	
— absorption in Papua New Guineans with leprosy. Cook, G. C. . . . .(A)	541
<b>Zaire,</b>	
Nocardia-like mycobacteria isolated from natural habitats in. Portaels, F., <i>et al.</i> . . . .(A)	408